Diagnostic assays using magnetic particles

By using magnetically sensitive beads and enzyme-conjugated antibody conjugates in a liquid handling device, and utilizing a magnetic field to retain them on the electrode for electrochemical measurement, the problems of contamination and poor reaction quenching caused by the unidirectional flow of liquid are solved, thus improving the accuracy and signal-to-noise ratio of detection.

CN118922716APending Publication Date: 2024-11-08OLSER DIAGNOSTICS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280092513.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-14
Filing Date
2022-12-22
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In existing liquid handling devices, multiple liquids flow through the measuring chamber, reaction zone, or other detection devices in the same direction, leading to contamination problems and insufficiently rapid and accurate reaction quenching, which affects the accuracy of diagnostic measurements.

Method used

The method employs an antibody conjugate with magnetically sensitive beads and an enzyme, which is retained on the electrode by a magnetic field. The analyte is then detected by electrochemical measurement, and the detection accuracy is improved by combining magnetic field adjustment and washing steps.

Benefits of technology

It achieves rapid and precise reaction quenching and contamination reduction, improving the signal-to-noise ratio and accuracy of diagnostic measurements.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922716A_ABST
    Figure CN118922716A_ABST
Patent Text Reader

Abstract

The present invention relates to a device and a method for determining an analyte in a biological sample by incorporating an immunoassay that magnetically captures beads on a sensor, which can be used in the field of immediate diagnostics.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to a device and a method for determining an analyte in a biological sample by immunoassay combined with magnetic capture of beads on a sensor, which can be used in the field of point-of-care diagnostics. Background Art

[0002] Diagnostic tests such as immunoassays are often used to detect specific analytes in samples. For example, antibody pairs that can bind to an analyte to form a sandwich that can be detected by an enzyme or label on one or more antibodies are well known and can be used for a variety of different analytes of interest. Antibodies against specific biomarkers such as testosterone or cortisol can be used to test the levels of these substances in saliva, blood or urine samples. The presence of the analyte is then determined using, for example, electrochemical measurements or optical measurements (such as fluorescence). Many electrochemical measurement techniques are known to those skilled in the art, such as electrochemical impedance spectroscopy, differential pulse voltammetry, square wave voltammetry, cyclic voltammetry, chronoamperometry, open circuit potential measurement, and chronopotentiometry.

[0003] Point-of-care testing provides subjects with convenient, immediate access to diagnostic tests, allowing for better and faster clinical decisions. However, integrating diagnostic tests into point-of-care devices or systems is challenging. Preparation of immunoassay samples may require mixing of multiple solutions and reagents with precise control of volumes and mixing times. Furthermore, the device is ideally automated to avoid the need for a medical professional to be present.

[0004] Existing liquid handling devices typically cause multiple liquids (e.g., sample liquids, reagents, or wash buffers) to flow through measurement chambers, reaction zones, or other detection devices in the same flow direction (i.e., different liquids flow sequentially through the same conduits and components of the device). This can lead to contamination problems because when the next liquid or reagent is added, some of the liquid or reagent involved in the previous step may still be present in the conduits, measurement chambers, reaction zones, or other detection devices. This contamination can reduce the accuracy of diagnostic assays.

[0005] Existing liquid handling devices allow multiple liquids to flow through a measurement chamber, reaction zone or other detection device in the same flow direction, and are unable to quickly, accurately and controllably quench reactions and / or bioreactions in the measurement chamber, reaction zone or other detection device. This is because the sequential linear flow of multiple reagents in the same direction cannot remove the previous liquid or analyte from the measurement chamber, reaction zone or other detection device quickly enough.

[0006] Therefore, there is a need to provide improved immunoassay techniques that can more accurately detect analytes of interest and improve signal-to-noise ratios. Summary of the invention

[0007] This Summary introduces concepts that are described in greater detail in the Detailed Description. It should not be used to identify essential features of the claimed subject matter, nor should it be used to limit the scope of the claimed subject matter.

[0008] The present invention provides a method for measuring an analyte of interest in a biological sample, comprising:

[0009] The biological sample is combined with a composition comprising:

[0010] magnetically sensitive beads conjugated to a first antibody or antigen binding portion thereof, the first antibody or antigen binding portion thereof being capable of binding the analyte of interest; and

[0011] a second antibody or antigen binding portion thereof conjugated to an enzyme, the second antibody or antigen binding portion thereof being capable of binding to the analyte of interest;

[0012] The magnetic sensitive beads are retained on the electrodes using a magnetic field;

[0013] contacting the magnetically sensitive beads with a substrate for the enzyme, wherein the enzyme substrate is converted by the enzyme into an electroactive molecule; and

[0014] Electrochemical measurements were obtained using the electrodes.

[0015] The present invention also provides a method for measuring one or more analytes of interest in a biological sample, comprising:

[0016] The biological sample is combined with a composition comprising:

[0017] magnetically sensitive beads conjugated to one or more antibodies or antigen binding portions thereof, wherein each antibody or antigen binding portion thereof is capable of binding one of said analytes of interest; and

[0018] one or more second antibodies or antigen binding portions thereof conjugated to an enzyme, wherein each second antibody or antigen binding portion thereof is capable of binding to one of the analytes of interest;

[0019] The magnetic sensitive beads are retained on the electrodes using a magnetic field;

[0020] contacting the magnetically sensitive beads with one or more enzyme substrates, wherein the enzyme substrates are converted by the enzymes into electroactive molecules; and

[0021] Electrochemical measurements were obtained using the electrodes.

[0022] In some embodiments, the method is capable of detecting at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 different analytes of interest. In some embodiments, each magnetically sensitive bead is conjugated to a plurality of different antibodies or antigen binding portions thereof, wherein each antibody or antigen binding portion thereof is capable of binding to one of the analytes of interest. In some embodiments, the magnetically sensitive beads include different groups of magnetically sensitive beads, wherein each group of magnetically sensitive beads is conjugated to a different antibody or antigen binding portion thereof, wherein each antibody or antigen binding portion thereof is capable of binding to one of the analytes of interest.

[0023] In some embodiments, the enzyme substrate is converted by the enzyme at the electrode into a soluble electroactive molecule. In some embodiments, the enzyme substrate is converted by the enzyme into an electroactive molecule that is precipitated on magnetically sensitive beads.

[0024] In some embodiments, the method further comprises:

[0025] The combined biological sample and composition are incubated to allow the one or more first antibodies and / or the one or more second antibodies to bind to the analyte of interest.

[0026] In some embodiments, the method further comprises:

[0027] Using a magnetic field to retain the magnetically sensitive beads in a fixed position; and

[0028] Wash the magnetically sensitive beads.

[0029] In some embodiments, the fixed location is at an electrode. In some embodiments, the fixed location is a location spatially remote from said electrode, optionally wherein the spatially remote location is a blank electrode or a non-functional electrode.

[0030] In some embodiments, the method further comprises:

[0031] retaining the magnetically sensitive bead in the first position using a magnetic field; and

[0032] The magnetically sensitive beads are washed by adjusting the magnetic field to retain the magnetically sensitive beads in the second position.

[0033] In some embodiments, the magnetic field is generated by a fixed magnet. In some embodiments, the magnetic field is generated by an electromagnet. In some embodiments, the magnetic field is adjusted by physically actuating the magnet. In some embodiments, the magnetic field is adjusted by controlling the current in the electromagnet.

[0034] In some embodiments, the magnetic field is located within a microfluidic device having a flow conduit, and wherein the magnetic field is adjusted by actuating a magnet in a direction perpendicular to the direction of flow within the flow conduit. In some embodiments, the magnetic field is located within a microfluidic device having a flow conduit, and wherein the magnetic field is adjusted by controlling a current in an electromagnet.

[0035] In some embodiments, the magnetically sensitive bead moves between the first position and the second position at least 20 times, such as at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 11 times, at least 12 times, at least 13 times, at least 14 times, at least 15 times, at least 16 times, at least 17 times, at least 18 times, or at least 19 times. In some embodiments, the magnetically sensitive bead moves between the first position and the second position 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 11 times, 12 times, 13 times, 14 times, 15 times, 16 times, 17 times, 18 times, 19 times, or 20 times, preferably 12 times.

[0036] In some embodiments, the magnetic field is adjusted so that the magnetically sensitive bead moves periodically between the first position and the second position. In some embodiments, the time interval between the magnetically sensitive bead being in the first position and being in the second position is about 0.01 seconds to about 5 seconds, about 0.05 seconds to about 5 seconds, about 0.1 seconds to about 5 seconds, about 0.2 seconds to about 5 seconds, about 0.3 seconds to about 5 seconds, about 0.4 seconds to about 5 seconds, about 0.5 seconds to about 5 seconds, about 1 second to about 5 seconds, about 2 seconds to about 5 seconds, about 3 seconds to about 5 seconds, about 4 seconds to about 5 seconds, about 0.01 seconds to about 4 seconds, about 0.05 seconds to about 4 seconds, about 0.1 seconds to about 4 seconds, about 0.2 seconds to about 4 seconds, about 0.3 seconds to about 4 seconds. seconds, about 0.4 seconds to about 4 seconds, about 0.5 seconds to about 4 seconds, about 1 second to about 4 seconds, about 2 seconds to about 4 seconds, about 3 seconds to about 4 seconds, about 0.01 seconds to about 3 seconds, about 0.05 seconds to about 3 seconds, about 0.1 seconds to about 3 seconds, about 0.2 seconds to about 3 seconds, about 0.3 seconds to about 3 seconds, about 0.4 seconds to about 3 seconds, about 0.5 seconds to about 3 seconds, about 1 second to about 3 seconds, about 2 seconds to about 3 seconds, about 0.01 seconds to about 2 seconds, about 0.05 seconds to about 2 seconds, about 0.1 seconds to about 2 seconds, about 0.2 seconds to about 2 seconds, about 0.3 seconds to about 2 seconds, about 0. 4 seconds to about 2 seconds, about 0.5 seconds to about 2 seconds, about 1 second to about 2 seconds, about 0.01 seconds to about 1 second, about 0.05 seconds to about 1 second, about 0.1 seconds to about 1 second, about 0.2 seconds to about 1 second, about 0.3 seconds to about 1 second, about 0.4 seconds to about 1 second, about 0.5 seconds to about 1 second, about 0.01 seconds to about 0.5 seconds, about 0.05 seconds to about 0.5 seconds, about 0.1 seconds to about 0.5 seconds, about 0.2 seconds to about 0.5 seconds, about 0.3 seconds to about 0.5 seconds, about 0.4 seconds to about 0.5 seconds, about 0.01 seconds to about 0.4 seconds, about 0.05 sec to about 0.4 sec, about 0.1 sec to about 0.4 sec, about 0.2 sec to about 0.4 sec, about 0.3 sec to about 0.4 sec, about 0.01 sec to about 0.3 sec, about 0.05 sec to about 0.3 sec, about 0.1 sec to about 0.3 sec, about 0.2 sec to about 0.3 sec, about 0.01 sec to about 0.2 sec, about 0.05 sec to about 0.2 sec, about 0.1 sec to about 0.2 sec, about 0.01 sec to about 0.1 sec, about 0.05 sec to about 0.1 sec, about 0.01 sec to about 0.05 sec, preferably about 3 sec to about 5 sec, and more preferably about 4 sec.

[0037] In some embodiments, the magnetically sensitive beads are washed with a washing solution and / or air. In some embodiments, the magnetically sensitive beads are washed sequentially and separately with a washing solution and air. In some embodiments, the magnetically sensitive beads are washed alternately with a washing solution and air at least twice, at least three times, at least four times, or at least five times, preferably wherein the magnetically sensitive beads are washed alternately with a washing solution and air twice.

[0038] In some embodiments, the biological sample is diluted prior to binding to the magnetically sensitive beads. In some embodiments, the electrode is a carbon ink electrode.

[0039] In some embodiments, the analyte of interest is brain natriuretic peptide or N-terminal pro-BNP. In some embodiments, the analyte of interest is cardiac troponin or cardiac troponin subunit I (cTnI).

[0040] In some embodiments, the one or more analytes of interest are selected from the list consisting of brain natriuretic peptide, N-terminal pro-BNP, cardiac troponin, and cardiac troponin subunit I (cTnI). In some embodiments, the one or more analytes of interest are N-terminal pro BNP and cardiac troponin subunit I (cTnI).

[0041] In some embodiments, the enzyme is horseradish peroxidase (HRP). In some embodiments, the enzyme is alkaline phosphatase (ALP). In some embodiments, at least one of the one or more second antibodies, or antigen-binding portions thereof, is conjugated to horseradish peroxidase (HRP) and at least one of the one or more second antibodies, or antigen-binding portions thereof, is conjugated to alkaline phosphatase (ALP).

[0042] In some embodiments, the substrate of the enzyme is selected from the list consisting of: 3,3',5,5'-tetramethylbenzidine (TMB), 2,2'-azinobis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS), o-phenylenediamine dihydrochloride (OPD), p-nitrophenyl phosphate (PNPP) and BCIP / NBT (a combination of BCIP (5-bromo-4-chloro-3-indolyl phosphate) and NBT (nitro blue tetrazolium)).

[0043] In some embodiments, the product of the enzymatic reaction is precipitated, optionally wherein the product is precipitated onto magnetically sensitive beads. In some embodiments, the substrate is 3,3',5,5'-tetramethylbenzidine (TMB), and the product of the enzymatic reaction is precipitated, optionally wherein the product is precipitated onto magnetically sensitive beads. In some embodiments, the substrate is BCIP / NBT (a combination of BCIP (5-bromo-4-chloro-3-indolyl phosphate) and NBT (nitro blue tetrazolium), and the product of the enzymatic reaction is precipitated, optionally wherein the product is precipitated onto magnetically sensitive beads.

[0044] In some embodiments, the electrochemical measurement indicates the concentration or amount of an analyte of interest. In some embodiments, the concentration or amount of an analyte of interest is determined by comparison to a reference solution.

[0045] In some embodiments, the electrochemical measurement is amperometry, voltammetry, potentiometry, impedance measurement or electrochemical impedance spectroscopy, preferably chronoamperometry. In some embodiments, the electrochemical measurement is differential pulse voltammetry (DPV).

[0046] In some embodiments, the measuring method is a sandwich immunoassay.In some embodiments, at least 50% (e.g., at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) of the beads, measured by weight %, remain on the surface of the electrode.

[0047] The present invention also provides a method for measuring an analyte of interest in a biological sample, comprising:

[0048] The biological sample is combined with a composition comprising:

[0049] magnetically sensitive beads conjugated to a first antibody or antigen binding portion thereof, the first antibody or antigen binding portion thereof being capable of binding the analyte of interest; and

[0050] a second antibody or antigen binding portion thereof conjugated to an enzyme, the second antibody or antigen binding portion thereof being capable of binding to the analyte of interest;

[0051] The magnetic sensitive beads are retained on the electrodes using a magnetic field;

[0052] contacting the magnetically sensitive beads with a substrate for the enzyme, wherein the enzyme substrate is converted by the enzyme into a precipitated electroactive molecule; and

[0053] Electrochemical measurements were obtained using the electrodes.

[0054] The present invention also provides a method for measuring one or more analytes of interest in a biological sample, comprising:

[0055] The biological sample is combined with a composition comprising:

[0056] magnetically sensitive beads conjugated to one or more antibodies or antigen binding portions thereof, wherein each antibody or antigen binding portion thereof is capable of binding one of said analytes of interest; and

[0057] one or more second antibodies or antigen binding portions thereof conjugated to an enzyme, wherein each second antibody or antigen binding portion thereof is capable of binding to one of the analytes of interest;

[0058] The magnetic sensitive beads are retained on the electrodes using a magnetic field;

[0059] contacting the magnetically sensitive beads with one or more enzyme substrates, wherein the enzyme substrates are converted by the enzymes into precipitated electroactive molecules; and

[0060] Electrochemical measurements were obtained using the electrodes.

[0061] In some embodiments, the method is capable of detecting at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 different analytes of interest. In some embodiments, the electroactive molecules are precipitated onto magnetically sensitive beads. In some embodiments, one or more analytes of interest are N-terminal pro BNP and cardiac troponin subunit I (cTnI). In some embodiments, the enzyme is horseradish peroxidase (HRP). In some embodiments, the enzyme is alkaline phosphatase (ALP). In some embodiments, at least one of the one or more second antibodies or antigen binding portions thereof is conjugated to horseradish peroxidase (HRP) and at least one of the one or more second antibodies or antigen binding portions thereof is conjugated to alkaline phosphatase (ALP).

[0062] In some embodiments, the substrate of the enzyme is selected from the list consisting of: 3,3',5,5'-tetramethylbenzidine (TMB), 2,2'-azinobis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS), o-phenylenediamine dihydrochloride (OPD), p-nitrophenyl phosphate (PNPP) and BCIP / NBT (a combination of BCIP (5-bromo-4-chloro-3-indolyl phosphate) and NBT (nitro blue tetrazolium)).

[0063] In some embodiments, the magnetically sensitive beads and the biological sample are incubated at a temperature of 10°C to 50°C, optionally 15°C to 45°C, optionally 20°C to 40°C, optionally 20°C to 30°C, optionally 25°C to 35°C, optionally 25°C, optionally 30°C, and optionally 40°C.

[0064] The present invention also provides a composition comprising: magnetically sensitive beads conjugated to a first antibody or an antigen binding portion thereof, the first antibody or the antigen binding portion thereof being capable of binding to an analyte of interest; and

[0065] A second antibody or antigen binding portion thereof conjugated to an enzyme, the second antibody or antigen binding portion thereof being capable of binding to the analyte of interest.

[0066] The present invention also provides a composition comprising: magnetically sensitive beads conjugated to one or more antibodies or antigen binding portions thereof, wherein each antibody or antigen binding portion thereof is capable of binding an analyte of interest; and

[0067] One or more second antibodies or antigen binding portions thereof conjugated to an enzyme, wherein each second antibody or antigen binding portion thereof is capable of binding to one of the analytes of interest.

[0068] In some embodiments of the composition of the present invention, each magnetically sensitive bead is conjugated to a plurality of different antibodies or antigen binding portions thereof, wherein each antibody or antigen binding portion thereof is capable of binding to one of the analytes of interest. In some embodiments of the composition of the present invention, the magnetically sensitive beads include different groups of magnetically sensitive beads, wherein each group of magnetically sensitive beads is conjugated to a different antibody or antigen binding portion thereof, wherein each antibody or antigen binding portion thereof is capable of binding to one of the analytes of interest.

[0069] In some embodiments of the compositions of the invention, the composition is capable of detecting at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 different analytes of interest. In some embodiments of the compositions of the invention, the analyte of interest is brain natriuretic peptide or N-terminal pro-BNP. In some embodiments of the compositions of the invention, the analyte of interest is cardiac troponin or cardiac troponin subunit I (cTnI). In some embodiments of the compositions of the invention, one or more analytes of interest are N-terminal pro BNP and cardiac troponin subunit I (cTnI). In some embodiments of the compositions of the invention, the enzyme is horseradish peroxidase (HRP) or alkaline phosphatase (ALP). In some embodiments of the compositions of the invention, at least one of the one or more second antibodies or antigen binding portions thereof is conjugated to horseradish peroxidase (HRP), and at least one of the one or more second antibodies or antigen binding portions thereof is conjugated to alkaline phosphatase (ALP).

[0070] In some embodiments of the compositions of the present invention, the substrate of the enzyme is selected from the list consisting of: 3,3',5,5'-tetramethylbenzidine (TMB), 2,2'-azinobis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS), o-phenylenediamine dihydrochloride (OPD), p-nitrophenyl phosphate (PNPP) and BCIP / NBT (a combination of BCIP (5-bromo-4-chloro-3-indolyl phosphate) and NBT (nitro blue tetrazolium)).

[0071] The present invention also provides a kit for performing the method according to the present invention, comprising:

[0072] magnetically sensitive beads;

[0073] An immunoassay device comprising an electrode; and

[0074] A magnet located near the chip is used to retain the magnetically sensitive beads near the electrodes.

[0075] In some embodiments of the kit of the present invention, the kit further comprises a means for retaining the magnetically sensitive beads at a separate location spatially away from the electrode. In some embodiments of the kit of the present invention, the means for retaining the magnetically sensitive beads at a separate location spatially away from the electrode is the same magnet used to retain the magnetically sensitive beads near the electrode. In some embodiments of the kit of the present invention, the means for retaining the magnetically sensitive beads at a separate location spatially away from the electrode is a second magnet configured to retain the magnetically sensitive beads at a separate location spatially away from the electrode. In some embodiments of the kit of the present invention, the magnet is a permanent magnet or an electromagnet.

[0076] In some embodiments of the kit of the present invention, the kit further comprises a means for retaining the magnetically sensitive beads at a separate location spatially away from the electrode. In some embodiments of the kit of the present invention, the means for retaining the magnetically sensitive beads at a separate location spatially away from the electrode is the same magnet used to retain the magnetically sensitive beads near the electrode. In some embodiments of the kit of the present invention, the means for retaining the magnetically sensitive beads at a separate location spatially away from the electrode is a second magnet configured to retain the magnetically sensitive beads at a separate location spatially away from the electrode. In some embodiments of the kit of the present invention, the magnet is a permanent magnet or an electromagnet.

[0077] The present invention also provides a method for measuring an analyte of interest in a biological sample, comprising:

[0078] The biological sample is combined with a composition comprising:

[0079] magnetically sensitive beads conjugated to a first antibody or antigen binding portion thereof, the first antibody or antigen binding portion thereof being capable of binding the analyte of interest; and

[0080] a second antibody or antigen binding portion thereof conjugated to an enzyme, the second antibody or antigen binding portion thereof being capable of binding to the analyte of interest;

[0081] The magnetic sensitive beads are retained on the electrodes using a magnetic field;

[0082] contacting the magnetically sensitive beads with a substrate for the enzyme, wherein the enzyme substrate is converted by the enzyme into a precipitated electroactive molecule; and

[0083] An electrochemical measurement is obtained using the electrode, wherein the biological sample and the composition are combined at a location spatially remote from the electrode, optionally wherein the spatially remote location is a blank electrode or a non-functional electrode.

[0084] The present invention also provides a method for measuring one or more analytes of interest in a biological sample, comprising:

[0085] The biological sample is combined with a composition comprising:

[0086] magnetically sensitive beads conjugated to one or more antibodies or antigen binding portions thereof, wherein each antibody or antigen binding portion thereof is capable of binding one of said analytes of interest; and

[0087] one or more second antibodies or antigen binding portions thereof conjugated to an enzyme, wherein each second antibody or antigen binding portion thereof is capable of binding to one of the analytes of interest;

[0088] The magnetic sensitive beads are retained on the electrodes using a magnetic field;

[0089] contacting the magnetically sensitive beads with one or more enzyme substrates, wherein the enzyme substrates are converted by the enzymes into precipitated electroactive molecules; and

[0090] An electrochemical measurement is obtained using the electrode, wherein the biological sample and the composition are combined at a location spatially remote from the electrode, optionally wherein the spatially remote location is a blank electrode or a non-functional electrode.

[0091] In some embodiments, the magnetically sensitive beads are contacted with one or more enzyme substrates at a location spatially distant from the electrode. In some embodiments, the magnetically sensitive beads are washed with a wash solution and / or air at a location spatially distant from the electrode. In some embodiments, the magnetically sensitive beads are washed sequentially and separately with a wash solution and air at a location spatially distant from the electrode.

[0092] In some embodiments, the magnetically sensitive beads are washed at least twice, at least three times, at least four times, or at least five times with a washing solution and air alternately at a location spatially distant from the electrode, preferably wherein the magnetically sensitive beads are washed twice with a washing solution and air alternately at a location spatially distant from the electrode. In some embodiments, the biological sample and the composition are combined at a location spatially distant from the electrode, and then the magnetically sensitive beads are moved to the electrode to obtain an electrochemical measurement. In some embodiments, the magnetically sensitive beads are contacted with a substrate for one or more enzymes at a location spatially distant from the electrode, and then the magnetically sensitive beads are moved to the electrode to obtain an electrochemical measurement.

[0093] In some embodiments, the magnetically sensitive beads are contacted with one or more enzyme substrates at a location spatially remote from the electrode and then moved to the electrode to obtain an electrochemical measurement.

[0094] In some embodiments, the biological sample and the composition are combined at a location spatially distant from the electrode; and / or the magnetically sensitive beads are retained at a location spatially distant from the electrode and washed with a wash solution and / or air, and then the magnetically sensitive beads are moved to the electrode to obtain an electrochemical measurement, optionally wherein the spatially distant location for combining the biological sample and the composition is the same as the spatially distant location for washing.

[0095] In some embodiments, the biological sample and the composition are combined at a location spatially away from the electrode, the magnetically sensitive beads are contacted with one or more enzyme substrates at a location spatially away from the electrode; and / or the magnetically sensitive beads are retained at a location spatially away from the electrode and washed with a wash solution and / or air, and then the magnetically sensitive beads are moved to the electrode to obtain an electrochemical measurement, optionally wherein the spatially distant location for combining the biological sample and the composition, the spatially distant location for washing, and / or the spatially distant location for contacting the magnetically sensitive beads with one or more enzyme substrates are the same.

[0096] In some embodiments of the invention, a first antibody or antigen binding portion thereof capable of binding to the analyte of interest and a second antibody or antigen binding portion thereof capable of binding to the analyte of interest bind to the same portion or epitope of the analyte of interest. In a preferred embodiment of the invention, the first antibody or antigen binding portion thereof capable of binding to the analyte of interest binds to a first portion or epitope of the analyte of interest, and the second antibody or antigen binding portion thereof capable of binding to the analyte of interest binds to a second portion or epitope of the analyte of interest. In some embodiments, the first portion or epitope of the analyte of interest is distal to the second portion or epitope of the analyte of interest, thereby reducing steric hindrance of the binding of the two antibodies or antigen binding portions thereof to the same analyte of interest. BRIEF DESCRIPTION OF THE DRAWINGS

[0097] Embodiments of the present invention will now be described by way of example only with reference to the accompanying drawings, in which:

[0098] Figure 1 : A. Comparison of signals with and without magnetic actuation after being pulled down onto the electrode. B. Visualization of beads dispersing onto the electrode after pulling down the magnetic particles, with and without magnetic actuation.

[0099] Figure 2 : Evaluation of the actuation method introduced during the wash process of the bead assay for samples containing 0 ng / L analyte (chronoamperometry after 60 seconds).

[0100] Figure 3: Evaluation of the possible wash volume reduction when using the magnet actuation method during the wash process of the bead assay between samples containing 0 pg / ml and 100 pg / ml analyte (chronocurrent after 60 seconds).

[0101] Figure 4 : Improvement in signal-to-noise ratio using the magnet-actuated method between samples containing 0 ng / L and 50 ng / L analyte (chronoamperometry after 60 seconds).

[0102] Figure 5 : For samples containing 100 ng / L analyte, resuspension of beads using the air-liquid interface (chronoamperometry after 60 seconds).

[0103] Figure 6 : Differential pulse voltammetry (DPV) measurements of troponin at concentrations of 0 ng / ml and 50 ng / ml in troponin-free serum. N=16 per group, peak height nA recorded.

[0104] Figure 7 : Graph of the signal-to-noise ratio (S / N) of two concentrations of troponin, 0 ng / ml and 50 ng / ml. N=16 per group.

[0105] Figure 8 : Isometric view of an exemplary liquid handling device.

[0106] Fig. 9 :show Figure 8 An exploded view of the components of the liquid handling device.

[0107] Fig.10 : Figure 8 A top cross-sectional view of a liquid handling device is shown.

[0108] Fig.11 : Figure 8 An isometric bottom view of a first rigid layer of a liquid handling device is shown.

[0109] Fig.12 : Available in Figure 8 A top view of a fluidics layer implemented in a liquid handling device is shown.

[0110] Fig.13 : Fig.12 Bottom view of an alternative fluid layer is shown. DETAILED DESCRIPTION

[0111] Suitable microfluidic devices

[0112] According to the first aspect of the present disclosure, the method of the present invention can be performed on a liquid processing device, which includes: a first rigid layer and a second rigid layer; a fluid layer arranged between the first rigid layer and the second rigid layer; wherein the fluid layer is formed by an elastomer; and wherein the fluid layer includes a channel network; and a fluid network including a plurality of conduits, wherein the plurality of conduits are at least partially defined by the channel network in the fluid layer.

[0113] Regardless of the bonding process used to seal the network (e.g., pressure sensitive adhesive (PSA) tape, laser welding, etc.), the use of channels set in the elastomeric layer provides improved fluid network sealing. This is because the elastomeric layer acts as a compliant layer when the elastomeric layer is sealed against another layer. In addition, the provision of channels in the compliant elastomeric layer allows the channels to be compressed so that valves can be set in the liquid handling device. Therefore, the flow of liquid in the liquid handling device can be controlled by compressing the channels in the elastomeric layer, which causes the valves of the liquid handling device to close. The use of a single layer of channel network also simplifies the construction of the liquid handling device.

[0114] The liquid handling device may further include a plurality of valves. Each of the plurality of valves may be configured to close a corresponding one of the plurality of pipes. The valves allow for control of the flow of liquid within the liquid handling device.

[0115] Each of the plurality of valves may include a deformable valve region disposed in the fluid layer. Each deformable valve region may be deformed into a deformed state in which a corresponding one of the plurality of pipes is blocked. Providing the deformable valve region in the fluid layer simplifies the construction of the liquid treatment device because the fluid layer implements the conduit of the device and the valve of the device.

[0116] The fluid layer may include a first face configured to face the first rigid layer and a second face configured to face the second rigid layer. At least a portion of the channel network may be disposed in the second face. Each deformable valve region may include a depression in the first face of the fluid layer. The depression may be aligned with a corresponding channel of at least a portion of the channel network disposed in the second face. Providing the depression in the first face of the fluid layer reduces the volume of material that needs to be deformed in order to close each valve of the liquid treatment device. This reduces the force required to close each valve.

[0117] A subset of the channel network may be provided in the first side. Providing channels on both sides of the fluidic layer means that the available area for providing corresponding bonding areas around the channels is increased, which is particularly important in view of the limited space available on the fluidic layer due to the small size of the instant device. Providing channels in the first side also allows the channels of the fluidic layer to cross, which means that more complex channel networks can be achieved.

[0118] The first rigid layer may include a plurality of openings. Each deformable valve region may be accessible through one of the plurality of openings. Providing openings in the rigid layer means that the liquid handling device has a rigid housing while allowing the valve to be actuated by applying an external force (e.g., from an actuator of the analytical device).

[0119] The liquid handling device can also include a plurality of openings extending through at least a portion of the thickness of the fluid layer. Each of the plurality of openings can be in fluid communication with a conduit in the plurality of conduits. The plurality of openings can include a first plurality of openings and a second plurality of openings. The second plurality of openings can be different from the first plurality of openings. The plurality of openings allow the fluid in the fluid layer (i.e., liquid or air provided by a pneumatic supply system) to be communicated with the fluid components in other layers.

[0120] The liquid handling device may also include a plurality of ports configured to provide a seal for the pneumatic interface. Each of the plurality of ports may include: a protrusion protruding from the surface of the fluid layer; and a corresponding opening in the first plurality of openings. A corresponding opening in the first plurality of openings may extend through the protrusion. Implementing the port in the elastomeric fluid layer allows the port to form a seal with the pneumatic interface. This is because when a force is applied to the port through the pneumatic interface (e.g., a pneumatic actuator of a pneumatic supply system), the fluid layer acts as a compliant layer. Providing the port in the same fluid layer as the channel network also simplifies the construction of the liquid handling device. The fluid communication between the port and the conduit allows the liquid to move within the conduit when pneumatic pressure is applied via the port.

[0121] Each protrusion may have a truncated cone shape. The truncated cone shape of the protrusion helps to form a seal between the port and the pneumatic interface. This is because the truncated cone shape causes the cross-section of the protrusion to narrow while the height above the surface increases. In other words, because the truncated cone shape provides an inclined wall, the truncated cone shape causes the top of the protrusion to have less material than the bottom of the protrusion. The reduced cross-sectional area at the top of the protrusion means that less material needs to be deformed through the pneumatic interface in order to provide a seal around the port. Less material to deform means that a smaller amount of force needs to be applied to compress the port.

[0122] Each opening in the first plurality of openings may have a diameter that increases with increasing height above the surface of the fluid layer. This further reduces the amount of material at the top of the protrusion, thereby requiring less force to deform the port.

[0123] Each protrusion may include an annular edge around the open end of the protrusion. The annular edge may define the minimum cross-sectional area of ​​the protrusion. The annular edge provides a further reduced amount of material at the top of the protrusion, which means that the force required to deform the protrusion is reduced.

[0124] One or more of the plurality of ports may further include: a plurality of support ribs. Each of the plurality of support ribs may extend between the protrusion and a surface of the fluid layer from which the protrusion protrudes. The support ribs help prevent excessive deformation of the port when force is applied to the port through the pneumatic interface.

[0125] The first rigid layer may include a plurality of openings. Each port may be accessible through one of the plurality of openings. Providing openings in the rigid layer means that the liquid handling device has a rigid housing while allowing pneumatic pressure to be applied to the port using an external pneumatic interface (e.g., a pneumatic actuator of an analytical device).

[0126] Each of the plurality of ports can be in fluid communication with one of the plurality of conduits via a corresponding groove in the second rigid layer. The groove prevents liquid from reaching the port connected to the pneumatic interface. Therefore, the groove prevents liquid from reaching the pneumatic interface, particularly during the process of pumping liquid. Such liquid may potentially contaminate or damage the pneumatic interface (e.g., the pneumatic interface in the analytical device). Specifically, any liquid extracted from the channel of the fluid layer during the pumping process converges at the bottom of the groove and does not reach the port. Therefore, any liquid extracted from the channel will not be sucked into the pneumatic interface via the port.

[0127] The liquid treatment device may further include at least one liquid storage capsule disposed over two openings of the second plurality of openings. Disposing the liquid storage capsule over the openings allows the fluid network to connect to the liquid storage capsule. This also allows the capsule to deform into the openings, thereby forming an opening in the capsule.

[0128] The fluid layer may include one or more chambers. Each of the one or more chambers is fluidically connected to one of the multiple conduits. Providing the chamber in the fluid layer simplifies the structure of the liquid treatment device. Specifically, providing one or more chambers in the fluid layer expands the function of the fluid layer.

[0129] The fluid layer may include a convex portion extending from the face of the fluid layer. The convex portion may include a plurality of cavities. Each of the one or more chambers may be at least partially defined by a corresponding one of the plurality of cavities. The provision of a convex portion extending from the face of the fluid layer means that the volume of the chamber is not limited by the thickness of the fluid layer. Thus, an increased chamber capacity may be provided.

[0130] The liquid handling device may further include a sealing membrane. A plurality of conduits may be defined by a network of channels in the fluid layer and the sealing membrane. The compliance of the elastomeric fluid layer assists the sealing membrane in sealing the channels.

[0131] Each channel comprises a groove disposed in the surface. Each channel thus has an open cross section. In other words, the cross section of each channel is not sealed. Each conduit comprises: (i) a channel that is sealed (e.g., by a sealing layer) to provide a closed cross section; or (ii) a hole or tunnel that at least partially extends through the body.

[0132] Figure 8 is an isometric view of a liquid handling device in the form of a diagnostic cartridge 100 (e.g., a microfluidic cartridge). Fig. 9 As can be seen from the exploded view shown, the cartridge 100 includes a number of components.

[0133] Specifically, the box 100 includes a first portion 200 and a second portion 500, each of which is formed of a rigid material. Figure 8 The first portion 200 is the upper portion and the second portion 500 is the lower portion. The first portion 200 and the second portion 500 together define the housing of the box 100. Specifically, the first portion 200 includes a rigid surface 250 that defines the upper surface of the box 100. Similarly, the second portion 500 includes a rigid surface 570 (such as a rigid surface 570) that defines the lower surface of the box 100. Figure 8 Back to Fig. 9 As can be seen, the first portion 200 further includes a side wall 252 engaged with the rigid surface 250, and the second portion 500 further includes a side wall 572 engaged with the rigid surface 570. The side wall 252 of the first portion 200 cooperates with the side wall 572 of the second portion 500 to define the side wall of the box 100.

[0134] The cartridge 100 further includes a fluidic layer 300 disposed within a housing defined by the first portion 200 and the second portion 500. Specifically, the fluidic layer 300 is disposed between the rigid surface 250 of the first portion 200 and the rigid surface 570 of the second portion 500. Thus, the fluidic layer 300 is disposed between a first rigid layer in the form of the rigid surface 250 and a second rigid layer in the form of the rigid surface 570. The fluidic layer 300 is formed of an elastomeric material, such as a thermoplastic elastomer (TPE), such as a silicone-based TPE or styrene-ethylene-butylene-styrene (SEBS); polydimethylsiloxane (PDMS); or liquid silicone rubber (LSR).

[0135] As follows Fig.12Described in more detail, the first surface 308 of the fluid layer 300 includes a plurality of valve areas 302. The box 100 is received in an analytical device including an actuator, which applies a force to the valve area 302 of the fluid layer 300 to close one or more conduits within the box 100. The properties of the material used for the fluid layer 300 depend on the available force that can be applied to the valve area 302 of the fluid layer 300 by the actuator. Two important properties are the hardness of the material and the relaxation time of the material (i.e., the time it takes for the material to return to its original shape after deformation). Examples of suitable materials include the elastomeric materials listed above. In some embodiments, the fluid layer 300 can be a medical grade material to prevent the fluid layer 300 from reacting with the reagents used in the diagnostic test or assay.

[0136] As described in more detail below, the fluidic layer 300 includes a network of channels 304 that are (at least partially) disposed in a second surface 310 of the fluidic layer 300 that is opposite the first surface 308. The cartridge 100 also includes a fluidic network that includes a plurality of conduits that are at least partially defined by the network of channels 304 in the fluidic layer 300. Specifically, the conduits are defined by: (i) the network of channels 304 in the fluidic layer 300; (ii) the sealing layer 400 (e.g., Fig. 9 ), which is configured to seal the channels 304 in the second surface 310 of the fluid layer 300; and optionally (iii) a sealing layer (not shown), which is configured to seal any channels 304 in the network provided in the first surface 308.

[0137] Providing channels 304 in the elastomeric fluid layer 300 improves the sealing of the fluid layer, regardless of which bonding process is used to seal the network of channels 304 (e.g., pressure-sensitive adhesive tape, laser welding, etc.). This is because when the elastomeric fluid layer 300 is sealed against another layer (such as the sealing layer 400), the elastomeric fluid layer 300 acts as a compliant layer. In addition, the use of an elastomeric material in the fluid layer 300 means that the channels 304 can be compressed to close the corresponding conduits. This means that a single layer can be used to implement the channels 304 and the valves (i.e., the valve area 302), thereby providing a simple box construction.

[0138] Back to Fig. 9 As shown in the exploded view, it can be seen that the box 100 also includes: a label 110, which is arranged to cover at least a portion of the rigid surface 250 of the first part 200; a plurality of liquid storage capsules 120, which are arranged between the fluid layer 300 and the first surface 250 in the box 100; and a sealing tape 130, which is arranged to seal one or more chambers 332 in the fluid layer 300.

[0139] Fig. 9The cartridge 100 is also shown to further include: a flow cell strip 140 including a plurality of openings 142, each opening 142 partially defining a corresponding measurement chamber 610 of the cartridge 100; a sensor strip 150 including a plurality of sensors, each sensor being in fluid communication with a corresponding one of the measurement chambers 610; and a pair of absorbent waste pads 160, each absorbent waste pad being arranged to fit into a corresponding waste chamber disposed in the second portion 500. In some embodiments, the flow cell strip 140 is absent, and the openings 142 that partially define the measurement chambers 610 are disposed in an alternative sealing layer.

[0140] like Figure 8 and Fig. 9 As shown, the first portion 200 includes a receiver in the form of a cylinder 202 configured to receive a portion of a liquid storage container, such as a blood collection tube (e.g., Vacutainer (RTM) blood collection tube manufactured by Becton, Dickinson and Company of Franklin Lakes, New Jersey, USA). Blood collection tubes typically contain a certain volume of liquid (e.g., blood) and a head space containing a certain volume of gas.

[0141] The disclosed assays are not limited to biological samples from a particular source. The disclosed assays can also be performed from a capillary blood sample, a plasma sample, or any other suitable receptacle containing a biological sample (eg, a blood sample) from a subject.

[0142] Fluid Layer

[0143] exist Fig.12 and Fig.13 In the embodiment of the fluid layer shown, the channel 304 is arranged in the first surface 308 and the second surface 310 of the fluid layer 300. It is challenging to configure the network of fluid channels in a limited space. The instant device is designed to be smaller, which limits the available space for laying the channel and the corresponding bonding area around it (that is, for bonding to the sealing layer 400) on the fluid layer 300. Implementing the channel 304 on the two surfaces 308, 310 of the fluid layer 300 allows, for example, the channel 304 for transporting air (for example, for clearing the measurement chamber, or for removing liquid from the liquid storage capsule 120) to be moved to the first surface 308 without affecting the liquid flow. The channel 364 is also arranged in the first surface 308 to allow the channel 304 of the fluid layer 300 to cross, which means that a more complex network of channels 304 can be achieved.

[0144] In the embodiment of the fluidic layer 300, the valve region 302 is still disposed in the first surface 308 of the fluidic layer 300. Therefore, the channel 304 in the first surface 308 is a channel 304 that does not pass from under the valve region 302, or a channel 304 having a first portion in the first surface 308 and a second portion in the second surface 310. For example, the second portion of the channel 304 can be a portion of the channel 304 that passes under the valve region 302. Two of these portions of the channel 304 can be connected by a vertical or inclined conduit that passes through the thickness of the fluidic layer 300.

[0145] exist Fig.12 and Fig.13 Various examples of channels 304 having portions located in two surfaces 308, 310 are shown in FIG. Fig.12 and Fig.13 The channel 304a in the embodiment includes a first portion 382a disposed in the second surface 310, a second portion 382b disposed in the first surface 308, and a third portion 382c disposed in the second surface 310. The first portion 382a covers the first groove 514a ( Fig. 9 The third portion 382c extends between a point above the fluid layer 300 and a first through hole 384a in the fluid layer 300. The second portion 382b extends between the first through hole 384a and the second through hole 384b in the fluid layer. When the box 100 including the fluid layer 300 is assembled, the third portion 382c extends between the second through hole 384b and the opening 386, and the liquid storage capsule 120 can be arranged above the opening 386. By arranging portions of the channel 304a on both surfaces 308, 310, the channel 304b can span the channel 304a (as shown). Fig.12 and Fig.13 shown).

[0146] Liquid storage capsules

[0147] Fig.10 Also shown is the arrangement of a plurality of liquid storage capsules 120 within the box 100. Specifically, the liquid storage capsules 120 are sealed to the fluid layer 300 using a sealing tape 180. Fig.10 The sealing tape 180 is shown to include openings that allow the fluid layer 300 to protrude upwardly (i.e., the pneumatic port 312 and the protrusion 330 that defines the chamber 332). Fig.10 As shown, each liquid storage capsule 120 includes an inlet chamber 122, a main chamber 124 storing a liquid (such as a liquid reagent), and an outlet chamber 126. A sealing layer (such as a sealing foil) is used to seal the chambers 122, 124, 126 of each liquid storage capsule 120. The inlet chamber 122 and the outlet chamber 126 include corresponding recesses 128a, 128b in the top surface of the chamber, respectively.

[0148] Fig.10 The liquid storage capsule 120 shown includes two smaller liquid storage capsules 120a and two larger liquid storage capsules 120b. The smaller liquid storage capsules 120a are aligned so that the recesses 128a, 128b of the smaller storage capsules 120a are all in a straight line. Each larger liquid storage capsule 120b is arranged perpendicular to the corresponding smaller liquid storage capsule 120a so that the larger liquid storage capsules 120b are parallel to each other.

[0149] As explained in more detail below, each liquid storage capsule 120 is located over two openings 350 in the fluidic layer 300. Specifically, the inlet chamber 122 of the liquid storage capsule 120 covers a first opening of the openings 350, and the outlet chamber 126 of the liquid storage capsule 120 covers a second opening of the openings 350. When a force is applied to the recesses 128a, 128b of the liquid storage capsule 120, the material of the liquid storage capsule 120 deforms into each opening 350. When sufficient force is applied, the deformation of the liquid storage capsule 120 into the opening 350 causes a sealing layer (e.g., foil) used to seal the capsule 120 to rupture.

[0150] In an alternative embodiment, the inlet chamber 122 and the outlet chamber 126 may not include the recess 128. Instead, a force may be directly applied to a portion of the inlet chamber 122 and the outlet chamber 126 to deform the liquid storage capsule 120.

[0151] Fig.11 is an isometric bottom view of the first portion 200. Fig.11 As shown, the first portion 200 includes an actuatable portion 240 (e.g., an actuatable platform) that is actuatable from a first position to a second position, in which the actuatable portion 240 does not deform the liquid storage capsule 120 and in which the actuatable portion 240 deforms the liquid storage capsule 120.

[0152] The actuatable portion 240 is U-shaped so that it can be deformed toward each liquid storage capsule 120. The U-shape of the actuatable portion 240 also allows the actuatable portion 240 to bypass the protrusion 330 extending from the first surface 308 of the fluidic layer 300.

[0153] like Fig.11As shown, the lower side of the actuatable portion 240 includes four pairs of protrusions 242. Each pair of protrusions 242 extends toward the liquid storage capsule 120 and is aligned with the recesses 128a, 128b of one of the liquid storage capsules 120. Therefore, when the actuatable portion 240 is moved to the second position, the protrusions 242 engage with the recesses 128a, 128b of the capsule 120. In an alternative embodiment, the liquid storage capsule 120 may not include the recesses 128a, 128b, in which case the protrusions 242 may engage a portion of the inlet chamber 122 and the outlet chamber 126 of each liquid storage capsule 120 (e.g., the flat or domed upper surface of the inlet chamber 122 and the outlet chamber 126).

[0154] The underside of the actuatable portion 240 also includes four concave areas 244. Each concave area 244 is located between two protrusions 242. Each concave area 244 is configured to accommodate the main chamber 124 of its corresponding liquid storage capsule 120 when the actuatable portion 240 is in the second position. This means that when the actuatable portion 240 is in the second position, the main chamber 124 is not deformed by the actuatable portion 240.

[0155] Given that the protrusion 242 extends from a single actuatable portion 240, actuation of the actuatable portion 242 to the second position causes each of the plurality of capsules 120 to deform simultaneously. Thus, all capsules 120 within the cartridge 100 may be pierced by a single movement of the actuatable portion 240.

[0156] In an alternative embodiment, the actuatable portion 240 may include two groups of protrusions 242: a first group of protrusions, each of which extends a first distance toward the recess 128 of the liquid storage capsule 120; and a second group of protrusions, each of which extends a second distance toward the recess 128 of the liquid storage capsule 120, wherein the second distance is less than the first distance.

[0157] This alternative embodiment allows for piercing of the liquid storage capsule 120 in two stages. When the actuatable portion 240 is moved to the second position (as described above), the capsule 120 aligned with the first set of projections is pierced first. However, in order to pierce the capsule 120 aligned with the second set of projections, the actuatable portion 240 is actuated beyond the second position to the third position (because the second set of projections is shorter). Thus, this alternative embodiment allows for the release of liquid (e.g., liquid reagent) from some capsules before other capsules are pierced.

[0158] Thus, the fluid workflow steps include, for example, that the liquid reagent stored in the first and second capsules may be intact before the liquid reagent is released from the third and fourth capsules (e.g., if the liquid reagent in the third and fourth capsules is needed at a later stage of the fluid workflow). Additional sets of projections extending different distances from the actuatable portion 240 may be implemented to further stagger the release of liquid from the capsules 120.

[0159] Devices that allow bidirectional flow

[0160] Immunoassays rely on delivering liquids in a controlled manner. The volume of liquid delivered and the time of interaction are critical to the success and reproducibility of the assay. In addition, heterogeneous immunoassays require washing steps to remove unbound antibodies, unbound antigens, and enzyme labels from the detection surface. Reagents can become trapped in the liquid flow path and then interact with each other in nonspecific reactions. This can increase background signal, thereby reducing assay sensitivity, dynamic range, and precision. By using different flow paths and / or different liquid flow directions to add reagents that may cross-react, assay performance can be significantly improved.

[0161] The configuration of the liquid handling device providing bidirectional flow allows for rapid, precise and controllable quenching of reactions and / or biological interactions in the measurement chamber. The use of conduits with different flow directions also reduces contamination of each liquid in different method steps (i.e., reduces contamination of sample liquid in washing steps). This may not be easily achieved using known fluid handling devices (e.g., conventional microfluidic devices).

[0162] In one aspect, a liquid handling device may include: a sample chamber for receiving a sample; a measurement chamber for performing one or more measurements on the sample, wherein the measurement chamber includes a reaction zone; a first liquid reagent chamber; a sample chamber conduit connecting the sample chamber fluid to the measurement chamber; a sample chamber conduit valve for opening and closing the sample chamber conduit; a first liquid reagent chamber conduit connecting the first liquid reagent chamber fluid to the measurement chamber in a flow direction alternating with the sample chamber conduit; and a first liquid reagent chamber conduit valve for opening and closing the first liquid reagent chamber conduit.

[0163] The flow direction of the first liquid reagent chamber conduit into the measurement chamber can be at least ninety degrees to the flow direction of the sample chamber conduit into the measurement chamber. In one embodiment, the flow direction of the first liquid reagent chamber conduit into the measurement chamber is opposite to the flow direction of the sample chamber conduit into the measurement chamber. In some embodiments, the opposite flow direction is equivalent to a second flow direction that is 180 degrees to the first flow direction on the same horizontal plane of the device.

[0164] In some embodiments, the device further comprises: a second liquid reagent chamber; a second liquid reagent chamber conduit connecting the second liquid reagent chamber fluid to the measurement chamber in a flow direction alternating with the sample chamber conduit; and a second liquid reagent chamber conduit valve for opening and closing the second liquid reagent chamber conduit.

[0165] In some embodiments, the second liquid reagent chamber conduit is fluidly connected to the measurement chamber in an alternating direction with the sample chamber conduit and the first liquid reagent chamber conduit.

[0166] In some embodiments, the second liquid reagent chamber conduit is fluidly connected to the first liquid reagent chamber conduit, thereby providing a combined conduit that fluidly connects both the first liquid reagent chamber and the second liquid reagent chamber to the measurement chamber. In some embodiments, the flow direction of the combined conduit into the measurement chamber is at least ninety degrees to the flow direction of the sample chamber conduit into the measurement chamber.

[0167] In some embodiments, the flow direction of the combined conduit into the measurement chamber is opposite to the flow direction of the sample chamber conduit into the measurement chamber. In some embodiments, the opposite flow direction corresponds to a second flow direction 180 degrees from the first flow direction on the same horizontal plane of the device.

[0168] In some embodiments, the flow direction of the second liquid reagent chamber conduit into the measurement chamber is at least ninety degrees to the flow direction of the sample chamber conduit and / or the first liquid chamber conduit into the measurement chamber.

[0169] In some embodiments, the flow direction of the second liquid reagent chamber conduit into the measurement chamber is opposite to the flow direction of the sample chamber conduit and / or the first liquid chamber conduit into the measurement chamber. In some embodiments, the opposite flow direction is equivalent to a second flow direction that is 180 degrees to the first flow direction on the same horizontal plane of the device.

[0170] In some embodiments, the reaction zone comprises one or more electrodes. In some embodiments, the one or more electrodes comprise one or more electrodes selected from the following list: a counter electrode, a reference electrode, and a working electrode. In some embodiments, the one or more electrodes comprise at least one working electrode.

[0171] In some embodiments, the device includes two or more measuring chambers, each measuring chamber is fluidly connected to the sample chamber, and each measuring chamber is fluidly connected to the first liquid reagent chamber, wherein the device includes a corresponding number of sample chamber conduit valves and / or first liquid reagent chamber valves for independently controlling the flow of sample liquid and / or first liquid reagent into each measuring chamber.

[0172] In some embodiments, the device further comprises a second liquid reagent chamber, and wherein each measurement chamber is fluidically connected to the second liquid reagent chamber, and wherein the device comprises a corresponding number of second liquid reagent chamber conduit valves for independently controlling the flow of the second liquid reagent into each measurement chamber.

[0173] In some embodiments, the second liquid reagent chamber conduit is fluidly connected to the first liquid reagent chamber conduit, thereby providing one or more combined conduits that fluidly connect both the first liquid reagent chamber and the second liquid reagent chamber to the respective measurement chambers.

[0174] In some embodiments, any one or more of sample liquid, first liquid reagent and / or second liquid reagent can be independently controlled to enter the flow of each measuring chamber, to regulate the residence time of each liquid in each measuring chamber. In one embodiment, the flow of sample liquid can be independently controlled to enter each measuring chamber, to regulate the residence time of sample liquid in each measuring chamber. In one embodiment, the flow of first liquid reagent can be independently controlled to enter each measuring chamber, to regulate the residence time of first liquid reagent in each measuring chamber. In one embodiment, the flow of second liquid reagent can be independently controlled to enter each measuring chamber, to regulate the residence time of second liquid reagent in each measuring chamber.

[0175] In some embodiments, the flow rate of any one or more of the sample liquid, the first liquid reagent and / or the second liquid reagent is controlled so that the residence time of each liquid is a predetermined time period. In one embodiment, the flow rate of the sample liquid is controlled so that the residence time of the sample liquid is a predetermined time period. In one embodiment, the flow rate of the first liquid reagent is controlled so that the residence time of the first liquid reagent is a predetermined time period. In one embodiment, the flow rate of the second liquid reagent is controlled so that the residence time of the second liquid reagent is a predetermined time period.

[0176] In some embodiments, the device further comprises: a mixing zone located between the sample chamber and the measurement chamber, and wherein the mixing zone is fluidly connected to the sample chamber and the measurement chamber.

[0177] In some embodiments, the mixing zone includes a mixing chamber, wherein the mixing chamber is fluidly connected to the sample chamber conduit and the measurement chamber via a mixing chamber conduit.

[0178] In some embodiments, the device further comprises: a third liquid reagent chamber; a third liquid reagent chamber conduit connecting the third liquid reagent chamber fluid to the mixing zone, optionally wherein the third liquid reagent chamber conduit is connected to the mixing zone in a flow direction alternating with that of the sample chamber conduit; and a third liquid reagent chamber conduit valve for opening and closing the third liquid reagent chamber conduit.

[0179] In some embodiments, the flow rate of the third liquid reagent entering the mixing zone can be independently controlled to adjust the residence time of the third liquid reagent in the mixing zone. In some embodiments, the flow rate of the third liquid reagent is controlled so that the residence time of the third liquid reagent is a predetermined period of time.

[0180] In some aspects of the present invention, one or more of the first liquid reagent chamber, the second liquid reagent chamber, and the third liquid reagent chamber may be referred to as an auxiliary chamber. In one embodiment, the first liquid reagent chamber is referred to as an auxiliary chamber. In one embodiment, the second liquid reagent chamber is referred to as an auxiliary chamber. In one embodiment, the third liquid reagent chamber is referred to as an auxiliary chamber.

[0181] In one aspect, a method for performing a diagnostic assay may include sequentially moving a liquid from a sample chamber to a measuring chamber and moving a first liquid reagent into the measuring chamber from an alternating flow direction, the method comprising: filling the sample chamber with sample liquid; moving the sample liquid from the sample chamber to the measuring chamber; retaining the sample liquid in the measuring chamber for a predetermined period of time, moving the first liquid reagent from a first liquid reagent chamber to the measuring chamber in a flow direction alternating with the sample chamber liquid and performing a measurement, optionally wherein the first liquid reagent is retained in the measuring chamber for a predetermined period of time.

[0182] In some methods, the first liquid reagent is removed from the measurement chamber prior to taking a measurement.

[0183] In some embodiments, the method further comprises the step of moving liquid from the second liquid reagent chamber to the measurement chamber in a flow direction alternating with that of the sample liquid.

[0184] In one aspect, a method for performing a diagnostic assay may include sequentially moving a liquid from a sample chamber to a measuring chamber and moving a first liquid reagent and a second liquid reagent into the measuring chamber from alternating flow directions, the method comprising: filling the sample chamber with sample liquid; moving the sample liquid from the sample chamber to the measuring chamber; retaining the sample liquid in the measuring chamber for a predetermined period of time, moving the first liquid reagent from the first liquid reagent chamber to the measuring chamber in a flow direction alternating with the sample liquid; moving the second liquid reagent from the second liquid reagent chamber to the measuring chamber in a flow direction alternating with the sample liquid and performing a measurement, optionally wherein the first liquid reagent and the second liquid reagent are each retained in the measuring chamber for a predetermined period of time.

[0185] In some methods, the second liquid reagent is removed from the measurement chamber prior to taking the measurement.

[0186] In one aspect, a method for performing a diagnostic assay may include sequentially moving liquid from a sample chamber to a measuring chamber and moving a first liquid reagent and a second liquid reagent into the measuring chamber from alternating flow directions, the method comprising: filling the sample chamber with sample liquid; moving the sample liquid from the sample chamber to the measuring chamber; retaining the sample liquid in the measuring chamber for a predetermined period of time, moving the first liquid reagent from the first liquid reagent chamber to the measuring chamber in a flow direction alternating with the sample liquid; moving the second liquid reagent from the second liquid reagent chamber to the measuring chamber in a flow direction alternating with the sample liquid; moving an additional volume of the first liquid reagent from the first liquid reagent chamber to the measuring chamber in a flow direction alternating with the sample liquid and performing a measurement, optionally wherein the first liquid reagent and the second liquid reagent are each retained in the measuring chamber for a predetermined period of time.

[0187] In some methods, the flow direction of the first liquid reagent and / or the second liquid reagent is at least ninety degrees to the flow direction of the sample liquid into the measurement chamber, preferably wherein the flow direction of the first liquid reagent and / or the second liquid reagent is opposite to the flow direction of the sample liquid.

[0188] In some embodiments, the method further comprises the step of mixing the sample liquid with one or more additional reagents before moving the sample liquid into the measurement chamber.

[0189] In some methods, the sample liquid is mixed with a third liquid reagent from a third liquid reagent chamber in the mixing zone.

[0190] Method of the present invention

[0191] The present invention also provides methods of carrying out any of the methods of the present invention on any of the apparatus of the present invention as described above.

[0192] In some embodiments, the first liquid reagent is any liquid composition suitable for use as a washing solution in an immunoassay, such as a washing buffer. In some embodiments, the first liquid reagent is a liquid comprising one or more reagents selected from the following list: pH buffer (e.g., PBS, Tris, carbonate / bicarbonate, HEPES, MOPS, MES), a salt solution (e.g., NaCl, KCl, MgCl2), a detergent (e.g., Tween 20, Tween 80, Triton-X, CHAPS), and a stabilizer / blocking agent (e.g., BSA, casein).

[0193] In some embodiments, the first liquid reagent contains 0.05% (v / v) -20 Tris-buffered saline (TBS) and phosphate-buffered saline (PBS).

[0194] In some embodiments, the second liquid reagent is a detection reagent for immunoassay. In some embodiments, the second liquid reagent includes one or more reagents selected from the following: DAB (3,3'-diaminobenzidine), metal enhanced DAB, AEC (3-amino-9-ethylcarbazole), BCIP (5-bromo-4-chloro-3-indolyl phosphate), NBT (nitro blue tetrazolium chloride), TMB (3,3',5,5'-tetramethylbenzidine), ELF (enzyme labeled fluorescence) and OPD (o-phenylenediamine dihydrochloride), preferably wherein the second liquid reagent includes 3,3',5,5'-tetramethylbenzidine (TMB).

[0195] In some embodiments, the predetermined time period is from 1 second to 180 seconds (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 ,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,10 1, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141 170, 171, 172, 173, 174, 175, 176, 177, 178, 179 or 180 seconds).

[0196] In some embodiments, the predetermined time period is between 1 and 60 seconds (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 seconds).

[0197] In some embodiments, the predetermined time period is between 10 seconds and 30 seconds (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 seconds).

[0198] In some embodiments, the predetermined time period is 60 seconds to 180 seconds (e.g., 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, or 180 seconds).

[0199] In one aspect, a box for a microfluidic system is provided, wherein reagents are stored and integrated in a sealed reservoir in the box so that reagents do not flow into the microfluidic device before operation. This allows long-term storage of the box containing reagents while protecting the reagents and the microfluidic device from contamination and degradation. The advantages of the device described herein include that the valve in the microfluidic system has a simple geometry of construction, thereby allowing valve features and assemblies to be manufactured in a cost-effective manner. Another advantage is that its volume is very small compared to any non-integrated device outer valve, which is suitable for the smaller volume of fluid used in the microfluidic device.

[0200] In one aspect, a liquid handling device may include: a sample chamber for receiving a sample; a measuring chamber for performing one or more measurements on the sample, wherein the measuring chamber includes a reaction zone; a first liquid reagent chamber, which is fluidically connected to the measuring chamber in a flow direction alternating with that of the sample chamber; a variable pressure source conduit for connecting the measuring chamber to a variable pressure source; a sample chamber conduit, which connects the sample chamber fluid to the measuring chamber; a sample chamber conduit valve for opening and closing the sample chamber conduit; a corresponding measurement chamber conduit for each measuring chamber, wherein each corresponding measurement chamber conduit connects the corresponding measurement chamber fluid to the measuring chamber; and a corresponding measurement chamber conduit valve for opening and closing each corresponding measurement chamber conduit.

[0201] The liquid handling device allows the first liquid reagent or the second liquid reagent to be transferred to the measurement chamber in a flow direction alternating with the sample liquid. This configuration allows the liquid reagent (e.g., buffer or detection reagent) to be transferred to the measurement chamber through a separate conduit through which no sample liquid has passed before. This configuration allows the reaction and / or biological interaction in the measurement chamber to be quenched quickly, accurately and controllably. The use of conduits with different flow directions also reduces the contamination of each liquid in the different method steps (i.e., reduces the contamination of the sample liquid in the washing step). This may not be easily achieved using known fluid handling devices (e.g., conventional microfluidic devices).

[0202] The liquid handling device allows the sample to be transferred from the sample chamber to the measuring chamber by reducing the pressure of the measuring chamber relative to the sample chamber. By controlling the pressure change in the measuring chamber, the volume of the sample transferred to the measuring chamber can be accurately controlled. In the measuring chamber, the sample liquid can react or mix with the reagent. The device allows the sample to be stored in the measuring chamber for a necessary period of time, such as the duration required to complete the reaction with the reagent. This may not be easily achieved using known fluid handling devices (such as conventional microfluidic devices).

[0203] The sample can be held in the measurement chamber while a measurement is performed, for example as part of a diagnostic test such as an immunoassay. Likewise, the sample volume transferred to the measurement chamber and the residence time in the measurement chamber can be precisely controlled.

[0204] The liquid treatment device may or may not be equipped with a variable pressure source. That is, the variable pressure source may be integrated into the liquid treatment device, but is preferably reversibly connected to the liquid treatment device and can therefore be equipped separately.

[0205] A variable pressure source is a pressure source that can apply or provide positive pressure changes and negative pressure changes. For example, the variable pressure source can be a syringe and can be controlled by a stepper motor. Other variable pressure sources and ways to control the variable pressure source are known to those skilled in the art.

[0206] The liquid handling device is not limited to having only one measurement chamber or only one variable pressure source.

[0207] The measurement chamber may be arranged to receive fluid from the sample chamber when a sample chamber conduit valve is opened and a negative pressure change is applied to one or more of the measurement chambers.

[0208] The reagent chamber can store reagents such as antibody or antigen-binding portion thereof or protein solution, antibody or antigen-binding portion thereof or protein powder, buffer solution, enzyme substrate such as 3,3′,5,5′-tetramethylbenzidine (“TMB”), etc., for mixing or reacting with the sample to facilitate measurement of the sample in the measuring chamber, such as performing a diagnostic test on the sample.

[0209] By controlling the pressure changes in the liquid handling device, the reagents in the reagent chambers can be easily mixed with the sample. By providing a measurement chamber surrounded by one or more reagent chambers, the device facilitates complex mixing or washing operations, such as operations with multiple steps, each step requiring precise volume control and timing, which may not be easily achieved using known fluid handling devices.

[0210] The one or more measurement chambers may include a first measurement chamber for performing a first measurement on a sample and a second measurement chamber for performing a second measurement on the sample. Thus, the liquid handling device may include: a first measurement chamber conduit that connects the first measurement chamber fluid to the sample chamber or the mixing chamber; a second measurement chamber conduit that connects the second measurement chamber fluid to the sample chamber or the mixing chamber; a first measurement chamber conduit valve that opens and closes the first measurement chamber conduit; and a second measurement chamber conduit valve that opens and closes the second measurement chamber conduit.

[0211] Thus, a single liquid handling device may be configured to receive only one sample in a sample chamber, but perform multiple measurements or diagnostic tests to determine multiple properties of the sample.

[0212] The one or more reagent chambers may include: one or more first dedicated reagent chambers for reagents used in diagnostic tests performed only in the first measurement chamber; one or more second dedicated reagent chambers for reagents used in diagnostic tests performed only in the second measurement chamber; and one or more shared reagent chambers for reagents used in diagnostic tests measured in both the first measurement and the second measurement chambers.

[0213] Typically, separate measurement chambers each require their own separate reagent source, however, by providing a shared reagent chamber that provides reagents (e.g., buffer solutions) common to two separate diagnostic tests or measurements, a more compact liquid handling device can be provided. The same dedicated reagent chamber stores reagents that can be selectively mixed with a sample for a specific diagnostic test or measurement, such as a specific antibody or protein, thereby providing a wider range of functionality to the device.

[0214] The liquid handling device including one or more reagent chambers may also include a mixing chamber for mixing the sample with a reagent from one of the one or more reagent chambers. Therefore, the device also includes: a mixing chamber conduit, wherein the mixing chamber conduit connects the mixing chamber fluid to the measurement chamber; and a mixing chamber conduit valve for opening and closing the mixing chamber conduit.

[0215] Once the reagent and sample are combined, the resulting composition can be shuttled (transferred back and forth) between the measurement chamber and the mixing chamber to speed up mixing of the reagent and sample (homogenize the reagent and sample) or to speed up dissolution of the reagent in the sample or other fluid.

[0216] The liquid handling device may further comprise a waste chamber and a waste chamber conduit, wherein the waste chamber conduit fluidically connects the waste chamber to the measuring chamber and / or the mixing chamber.

[0217] The waste chamber can be used to safely store excess sample and / or reagents, for example after a measurement is performed on the sample using a liquid handling device. In addition, the sample can be provided in excess to the mixing chamber and then transferred to another chamber (e.g., a measurement chamber) in a precise amount, while the excess sample is drained to the waste chamber. The precisely measured sample can then be transferred to a different chamber with a precisely known volume.

[0218] The liquid handling device may also include a waste chamber conduit valve for opening and closing the waste chamber conduit. Alternatively, the waste chamber conduit may connect the waste chamber fluid to the mixing chamber via the measuring chamber. Thus, after performing the measurement, the sample may be transferred directly from the measuring chamber to the waste chamber.

[0219] At least one of the one or more measurement chambers may include a plurality of electrodes. The plurality of electrodes may be used to perform electrochemical measurements. Alternatively or additionally, at least one of the one or more measurement chambers may include an element for performing optical measurements, such as a window.

[0220] Each catheter valve may be a pinch valve. A pinch valve may be operated by an external actuator that selectively applies pressure to the pinch valve to open or close the pinch valve. Alternatively, the catheter valves may be configured in a circular array so that they may be operated by an actuator with a circular array of actuating elements. A pinch valve is a valve that utilizes a pinching action to block the flow of a fluid.

[0221] The catheter valves of the above device may be configured so that only one valve is open at any given time. The catheter valves of the above device may be closed by default.

[0222] The chambers of the liquid handling device may include gas exchange ports for allowing air or any other ambient gas to enter and leave each chamber to balance pressure changes caused by the entry of liquid (eg, sample or reagent) into the corresponding chamber, although this is not required.

[0223] The liquid handling device can be made from conventional materials known to those skilled in the art, such as acrylic, glass, silicon, or polydimethylsiloxane (PDMS), using conventional methods, such as chemical etching, laser etching, routing, or molding.

[0224] The pressure change is applied via a variable pressure source conduit of the liquid handling device and can be applied using a variable pressure source (e.g., a syringe or any other device suitable for applying positive and negative pressure changes) connected to the variable pressure source conduit. The variable pressure source conduit can be connected to a measurement chamber or a mixing chamber. Alternatively, the variable pressure source conduit can be connected to another suitable component of the device to allow precise control of the pressure change of the entire device.

[0225] A method for operating a liquid handling device, wherein the liquid handling device includes one or more reagent chambers as described above, and the method may also include: opening a reagent chamber conduit valve corresponding to one of the one or more reagent chambers; reducing the pressure of a mixing chamber relative to one of the one or more reagent chambers; and closing the reagent chamber conduit valve corresponding to one of the one or more reagent chambers.

[0226] Thus, reagents can be transferred from the reagent chamber to the mixing chamber.

[0227] The method may also include increasing the pressure of the mixing chamber relative to one of the one or more reagent chambers before decreasing the pressure of the mixing chamber relative to one of the one or more reagent chambers so as to transfer the liquid (e.g., sample) in the mixing chamber to one of the one or more reagent chambers. Thus, if one of the one or more reagent chambers contains a dry or powdered reagent, the liquid in the mixing chamber may be used to suspend or dissolve the reagent and then transfer it to the measurement chamber.

[0228] When the liquid handling device includes a mixing chamber as described above, the method of operating the liquid handling device may also include: opening the mixing chamber conduit valve; increasing the pressure of the measuring chamber relative to the mixing chamber; reducing the pressure of the measuring chamber relative to the mixing chamber; and closing the mixing chamber conduit valve.

[0229] Thus, a mixture (e.g., a mixture of a sample and a reagent) can be shuttled back and forth between a measuring chamber and a mixing chamber or between one or more reagent chambers and a mixing chamber to speed up the mixing of the reagent and the sample (e.g., to homogenize the reagent and the sample) or to speed up the dissolution of the reagent in the sample.

[0230] The method may also include repeating one or more times increasing the pressure in the mixing chamber and decreasing the pressure in the mixing chamber before closing the mixing chamber conduit valve.

[0231] When the liquid handling device includes the waste chamber, the waste chamber conduit, and the waste chamber conduit valve as described above, the method of operating the liquid handling device may further include: closing one of the corresponding measurement chamber conduit valves; opening the waste chamber conduit valve; increasing the pressure of the measurement chamber relative to the waste chamber; and closing the waste chamber conduit valve. The method may further include closing one of the corresponding measurement chamber conduit valves.

[0232] Thus, liquid in the measurement chamber can be transferred to the waste chamber where it can be safely stored, for example after performing a measurement on a sample using the liquid handling device.

[0233] When the liquid handling device includes a waste chamber and a waste chamber conduit fluidly connecting the waste chamber to the mixing chamber via the measuring chamber, the method of operating the liquid handling device may further include increasing the pressure of the mixing chamber relative to the waste chamber after performing a measurement on the sample.

[0234] Thus, liquid in the mixing chamber may be transferred to a waste chamber where it may be safely stored, for example after performing a measurement on a sample using the liquid handling device.

[0235] When the one or more measurement chambers comprise a plurality of electrodes, the method of operating a liquid handling device may further comprise performing an electrochemical measurement on the sample using the plurality of electrodes.

[0236] When each conduit valve of the liquid handling device is a pinch valve, the method of operating the liquid handling device may further comprise opening or closing at least one pinch valve by operating the actuator. The pinch valves may be configured to be opened only one at a time (ie, only one pinch valve is open at any one time).

[0237] It should be understood that the above methods can be performed in combination with each other and in a variety of different orders or multiple times, depending on the needs of a given diagnostic test. The order of each method is not limited to the order presented in the above features, and one method does not need to be completed before another method begins. For example, a mixing method can be performed after the sample and reagent are introduced into the measurement chamber, but before at least a portion of the sample is transferred to the measurement chamber.

[0238] In another aspect, a method of performing a diagnostic test using a liquid handling device as described above comprises filling a sample chamber with a sample and performing one or more of the above methods. Optionally, the liquid handling device comprises one or more reagent chambers, and each of the one or more reagent chambers comprises a corresponding reagent for the diagnostic test.

[0239] In another aspect, a method of operating a liquid handling device may include opening a third liquid reagent chamber conduit valve and increasing or decreasing the pressure in a mixing chamber relative to the third liquid reagent chamber by a predetermined amount, thereby enabling the transfer of a metered volume of liquid between the mixing chamber and the third liquid reagent chamber. Thus, the liquid handling device includes: a mixing chamber; a third liquid reagent chamber; a third liquid reagent chamber conduit, wherein the third liquid reagent chamber conduit connects the third liquid reagent chamber fluid to the mixing chamber; and a third liquid reagent chamber conduit valve for opening and closing the third liquid reagent chamber conduit. Using a predetermined pressure change enables the transfer of a precise volume of liquid.

[0240] Increasing or decreasing the pressure in the measuring chamber or the mixing chamber relative to the auxiliary chamber by a predetermined amount may comprise applying a predetermined pressure change for a predetermined period of time.

[0241] When the pressure in the mixing chamber increases, a metered volume of liquid can be transferred from the mixing chamber to the auxiliary chamber. When the pressure in the mixing chamber decreases, a metered volume of liquid can be transferred from the auxiliary chamber to the mixing chamber.

[0242] In another aspect, a computer program may include computer executable instructions which, when executed by a system, cause the system to perform any of the above methods.

[0243] In another aspect, a system may include a processor configured to execute a computer program including computer executable instructions that, when executed by the system, cause the system to perform any of the above methods.

[0244] The system may be a point-of-care system or a diagnostic system and / or may be used to perform diagnostic tests on a sample.

[0245] The system may also include: one or more variable pressure sources configured to be connected to the liquid handling device; a variable pressure source controller for controlling the variable pressure source; an actuator configured to selectively open or close each of the plurality of pinch valves; and a liquid handling device as described above. The processor may be configured to control the variable pressure source controller to control the variable pressure source according to any of the above methods. The system may also include a memory for storing a computer program.

[0246] In some embodiments, the alternate flow direction may be at least ninety degrees from the first flow direction when measured on the same horizontal plane of the device. In some embodiments, the alternate flow direction may be between 90 and 180 degrees from the first flow direction when measured on the same horizontal plane of the device. In some embodiments, the alternate flow direction may be between 90 and 180 degrees from the first flow direction when measured on the same horizontal plane of the device. In some embodiments, the alternate flow direction may be between 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179 or 180 degrees.

[0247] Methods of performing immunoassays

[0248] The present invention is applicable to methods of performing immunoassays with sensors that include a device for magnetically retaining beads on the sensor surface. In some embodiments, the present invention can be used in one or more of the following areas: immunosensors, most notably in the context of point-of-care testing; electrochemical immunoassays; whole blood immunoassays and disposable cartridge-based immunoassays. The skilled artisan will appreciate that the general concepts disclosed herein are applicable to a variety of immunoassay methods and platforms.

[0249] The method of the present invention is applicable to various biological sample types (eg, blood, plasma, serum, urine, tissue fluid, and cerebrospinal fluid). The present invention is applicable to various immunoassays, including sandwich immunoassays and competitive immunoassays.

[0250] Sandwich immunoassay

[0251] Immunoassays are often used to detect a specific analyte in a sample. For example, antibody pairs that can bind to an analyte to form a sandwich that can be detected by an enzyme or microparticle label on one of the antibodies are well known and can be used for a variety of different analytes of interest. For example, antibodies against specific biomarkers such as testosterone or cortisol can be used to test the levels of these substances in saliva, blood, or urine samples.

[0252] The presence of the antibody-analyte sandwich can be detected by a variety of methods, including the use of electrochemical measurements. Some reported assays also utilize enzyme substrates to amplify the assay signal and thereby increase assay sensitivity by generating an insoluble precipitate that can be detected by electrochemical measurements.

[0253] Many biomarker or analyte assays of interest are performed on electrode devices. Typical sandwich assays use a primary capture antibody or antigen binding portion thereof and a secondary signal antibody or antigen binding portion thereof to bind to different sites of the analyte. Conventional sandwich assays rely on the immobilization of the capture antibody or antigen binding portion thereof and the removal of excess signal antibody or antigen binding portion thereof prior to reading. The signal generated is proportional to the amount of sandwich analyte. Without the target analyte, only signal noise is generated. For example, sandwich assays are used in pregnancy test devices.

[0254] In some embodiments of the invention, a biological sample (e.g., a whole blood sample) is collected and then altered by adding a reagent comprising magnetically sensitive beads to the biological sample. The beads preferably include an antibody or antigen-binding portion thereof to an analyte of interest immobilized on their outer surface.

[0255] The concentration of magnetically sensitive beads used can vary depending on the arrangement of the assay. In some embodiments, the sample is altered with magnetically sensitive beads to provide a concentration of at least 5 μg of dissolved beads per μl of sample, for example at least 10 μg per μl of sample, or at least 15 μg per μl of sample. Once the sample is mixed with the magnetically sensitive beads (preferably the magnetically sensitive beads include antibodies or antigen-binding portions thereof to the analyte of interest immobilized on their outer surface), an immunoassay such as an electrochemical immunoassay can be performed on the altered sample to determine the concentration of the analyte. In some embodiments of the invention, at least about 10,000 beads are used for each assay. In some embodiments, the volume of dissolved beads is less than about 1% of the total sample assay volume, and optionally less than about 0.1% of the total sample assay volume.

[0256] In the measuring step, in some embodiments, once a sandwich is formed between the analyte-specific antibody or antigen-binding portion thereof, the analyte and the signal antibody immobilized on the beads, a magnetic field is applied to attract the beads to a position that allows washing of the beads. The sample is then washed to a waste chamber while the beads (e.g., substantially all of the beads in the sample) are retained in a fixed position within the box (optionally at an electrode, or optionally in a position spatially separated from the electrode), and the sandwich on the magnetically sensitive beads is then exposed to a substrate that can react with the enzyme to form a product that can be detected electrochemically. An exemplary format is an electrochemical enzyme-linked immunosorbent assay.

[0257] Biological samples

[0258] In the present invention, the sample liquid can be any suitable biological sample containing the diagnostic biomarker of interest. In some embodiments, the biological sample can be a whole blood sample, a serum sample, a plasma sample, a saliva sample, a biopsy sample (e.g., a healthy tissue sample or a tumor sample), a urine sample, a semen sample, a tear sample, a sputum sample, a sweat sample, a mucus sample, a stool sample, a gastric juice sample, a peritoneal fluid sample, an amniotic fluid sample, a cystic fluid sample, a peritoneal fluid sample, a spinal fluid sample, or a synovial fluid sample, but a whole blood sample is particularly preferred. In a preferred embodiment of the present invention, the biological sample is a whole blood sample. The method may include the step of obtaining or providing a biological sample, or the sample may alternatively be obtained from an object, such as by an ex vivo method.

[0259] Biological samples obtained from a subject can be stored until needed. Suitable storage methods include freezing biological samples immediately after collection, within 2 hours after collection, or within up to two weeks after collection. Maintaining at -80°C can be used for long-term storage. One or more suitable preservatives can be added, or the sample can be collected in a test tube containing one or more suitable preservatives. It is preferred to analyze the sample immediately (or as soon as possible) after collection.

[0260] The methods of the present invention may include additional steps performed on biological samples. The sample fluid is considered to represent the biomarker status of the biomarker or analyte of interest in different patient disease states. Therefore, the methods of the present invention can use quantitative data of the biomarker or analyte of interest to determine the presence or severity of different disease states. The methods disclosed herein are particularly suitable for the analysis of human blood.

[0261] Before determining the status of a biomarker or analyte of interest, the sample may be subjected to additional processing. The sample may be enriched (e.g., to increase the concentration of the biomarker or analyte of interest being quantified), centrifuged, or diluted. In other embodiments, the sample is not subjected to any pretreatment and is used untreated (e.g., whole blood).

[0262] In some embodiments of the invention, before detection and quantification (i.e., measurement), the biological sample can be fractionated or enriched for specific biomarkers. The step of fractionation or enrichment can be any suitable pretreatment method step for increasing the concentration of the biomarker of interest in the sample. For example, the step of fractionation and / or enrichment can include centrifugation and / or filtration to remove cells or unwanted analytes or fractions from the sample, or increase the concentration of the biomarker of interest in a specific blood fraction. This method is known to technicians and can be used for any biomarker of interest in the enriched sample.

[0263] The method of the present invention can be carried out on a test sample from an object. Alternatively, multiple test samples from an object can be obtained, such as at least 2, at least 3, at least 4 or at least 5 samples from an object. A single assay can be performed on each sample to quantify one of the biomarker members, or a test in which all biomarkers are quantified can be performed on the sample. Each sample can be analyzed separately using the method of the present invention, or alternatively the method can include diagnosing multiple samples from a single object.

[0264] "Sample," "one or more samples," sample fluid, biological sample, or "sample of interest" are terms that may be used interchangeably in the singular or plural and are not intended to be limited to any particular number, and as used herein, may be any molecule or substance from which a user wishes to collect information. During the course of performing an assay, a sample may increase or decrease in size, volume, or content (e.g., by expansion, dilution, fractionation, or partitioning). Thus, during the course of performing an assay, a sample may be amplified and / or subdivided one or more times. In some embodiments, a sample contains or may contain a biomarker or analyte of interest.

[0265] As used herein, "liquid" is any free-flowing aqueous or lipophilic phase. The liquid may also include one or more reagents, reaction components, or samples of interest selected from the following: cells (including any eukaryotic or prokaryotic cells, including but not limited to cells selected from humans, animals, plants, fungi, bacteria, viruses, protozoa, yeasts, molds, algae, rickettsiae, and prions), proteins, peptides, antibodies, nucleic acid sequences, oligonucleotide probes, polymerases, buffers, dNTPs, organic and inorganic chemicals, and fluorescent dyes.

[0266] Embodiments are not limited to the microfluidic scale, but other applications on a larger scale are also contemplated.

[0267] Magnetic capture

[0268] In some embodiments of the invention, the immunosensor comprises electrodes and has a magnet, such as a permanent magnet or an electromagnet, located near the sensor (preferably below). The magnetic immunosensor of the invention provides a field greater than about 0.1 Tesla (e.g., 0.1 Tesla, 0.2 Tesla, 0.3 Tesla, 0.4 Tesla, or 0.5 Tesla, preferably 0.4 Tesla), and is capable of attracting and retaining magnetically sensitive beads in the range of about 0.05 mm to about 5 mm in the electrode region.

[0269] For example, the magnetic field can be measured, such as measuring the magnetic field over a substantially flat surface area of ​​the magnet. The skilled person will recognize that the permanent magnets can include ferrites or aluminum nickel cobalt (AlNiCo) magnets, which typically exhibit magnetic fields of 0.1 Tesla to 1 Tesla. Other high field permanent magnets including rare earth element alloys (such as neodymium alloys and samarium cobalt (SmCo) alloys) exhibit fields exceeding 1 Tesla, such as greater than 1.2 Tesla or greater than 1.4 Tesla.

[0270] In some embodiments, the magnetic field can be adjusted by physically actuating a permanent magnet or an electromagnet between one or more locations at different physical distances from a desired location (e.g., a sensor, or a spatially separate location for washing). For example, the magnetic field can be adjusted by physically actuating a permanent magnet or an electromagnet between two locations, a first location that is far from the desired location (e.g., a sensor, or a spatially separate location for washing) and a second location that is close to the desired location (e.g., a sensor, or a spatially separate location for washing), wherein at the second location the magnet provides a sufficiently large magnetic field to capture the magnetically sensitive beads at the desired location (e.g., a sensor, or a spatially separate location for washing).

[0271] In another embodiment, the magnet comprises an electromagnet, wherein the magnetic field is generated by the flow of electric current.The electric current may be provided by an analytical device, the cartridge containing the sensor being inserted into the analytical device and the sensor being in electrical contact with the analytical device.

[0272] Magnetic sensitive beads

[0273] In some embodiments of the invention, a biological sample (e.g., a blood sample) is mixed with magnetically sensitive beads. The magnetically sensitive beads can comprise any material known in the art that is easily moved by a magnet (e.g., a permanent magnet or an electromagnet) used in or in conjunction with an immunosensor cartridge of the invention. Therefore, the terms "magnetic" and "magnetically sensitive" in relation to the beads can be used interchangeably.

[0274] In some embodiments of the invention, the beads include a magnetic core, which is preferably fully or partially coated with a coating material. The magnetic core may include a ferromagnetic, paramagnetic, or superparamagnetic material. In a preferred embodiment, the magnetically sensitive beads include a ferrite core and an outer polymer coating. In a preferred embodiment, the magnetically sensitive beads are Magnetic beads are uniform, non-porous, superparamagnetic, monodisperse and highly cross-linked polystyrene microspheres composed of magnetic material uniformly dispersed throughout the bead. The magnetic material inside the beads consists of a mixture of hematite (γ-Fe2O3) and magnetite (Fe3O4). The iron content (Fe) of the beads in magnetic beads M-280 is 12wt%, and The iron content (Fe) of the beads in magnetic beads M-450 is 20 wt %. The magnetic beads are coated with a thin polystyrene shell that encapsulates the magnetic material and prevents leakage of the beads or ligands from being trapped inside the beads. The shell also protects the target from exposure to iron while providing a defined surface area for adsorption or coupling of various molecules.

[0275] The magnetic core may include one or more of the following: Fe, Co, Mn, Ni, metals including one or more of these elements, ordered alloys of these elements, crystals containing these elements, magnetic oxide structures (such as ferrites), and combinations thereof. In other embodiments, the magnetic core may include magnetite, hematite, or a divalent metal ferrite of a metal (such as Cu, Fe, Ni, Co, Mn, Mg, or Zn, or a combination of these materials).

[0276] Suitable materials for coating include synthetic polymers and biopolymers, copolymers and polymer blends, and inorganic materials. Polymeric materials can include various combinations of polymers of acrylates, siloxanes, styrene, acetates, alkyl glycols, alkyl olefins, alkylene oxides, polyparaxylene, lactic acid and glycolic acid. Biopolymer materials include starch or similar carbohydrates. Inorganic coating materials can include any combination of metals, metal alloys and ceramics. The example of ceramic material can include the oxide of hydroxyapatite, silicon carbide, carboxylates, sulfonates, phosphates, ferrites, phosphonates and periodic table IV group elements.

[0277] In other embodiments of the present invention, the magnetic beads may be formed from a non-magnetic substrate, such as a material selected from the group consisting of polystyrene, polyacrylic acid and dextran, on which a suitable magnetic coating is placed.

[0278] Taking into account the dispersion requirements of the magnetically sensitive beads, any appropriately sized magnetically sensitive beads that can be positioned with the magnets of the present invention can be used. In a preferred embodiment, at least 50% (measured in weight %) of the magnetically sensitive beads in the assay are retained on the electrode surface (or the surface of a spatially distant washing area). In some embodiments, at least 60%, 70%, 80%, 90% or 95% (measured in weight %) of the magnetically sensitive beads in a given sample are retained on the electrode surface (or the surface of a spatially distant washing area). As used herein, the term "spatially distant" or "spatially distant location" refers to any suitable area in which the magnetically sensitive beads can be retained (e.g., for washing) that does not substantially overlap with the electrode or detection area.

[0279] In some exemplary embodiments, the average particle size of the magnetically sensitive beads may be from 0.01 μm to about 10 μm, from about 0.05 μm to about 10 μm, from about 0.1 μm to about 10 μm, from about 0.2 μm to about 10 μm, from about 0.5 μm to about 10 μm, from about 0.8 μm to about 10 μm, from about 1 μm to about 10 μm, from about 2 μm to about 10 μm, from about 5 μm to about 10 μm, from about 0.01 μm to about 5 μm, from about 0.05 μm to about 5 μm, from about 0.1 μm to about 5 μm, from about 0.2 μm to about 10 μm, from about 0.5 μm to about 10 μm, from about 0.8 μm to about 10 μm, from about 1 μm to about 10 μm, from about 2 μm to about 10 μm, from about 5 μm to about 10 μm. 1μm to about 2μm, about 0.2μm to about 2μm, about 0.5μm to about 2μm, about 0.8μm to about 2μm, about 1μm to about 2μm, about 0.05μm to about 1μm, about 0.1μm to about 1μm, about 0.2μm to about 1μm, about 0.5μm to about 1μm, about 0.8μm to about 1μm, about 0.05μm to about 0.8μm, about 0.1μm to about 0.8μm, about 0.2μm to about 0.8μm, about 0.5μm to about 0.8μm, about 0.05μm to about 0.5μm, about 0.1μm to about 0.5μm, about 0.2μm to about 0.5μm, about 0.05μm to about 0.2μm, about 0.1μm to about 0.2μm, about 0.05μm to about 0.1μm. Preferably, the average particle size of the magnetically sensitive beads is about 1 μm.

[0280] As used herein, the term "average particle size" refers to the average longest dimension of particles (e.g., beads), such as the diameter of spherical particles, which is determined by methods well known in the art. The particle size distribution of the magnetically sensitive beads is preferably unimodal, but beads with multimodal distributions can also be used. Although spherical magnetically sensitive beads are preferably used, in other embodiments, other bead shapes and structures (e.g., elliptical, sub-spherical, cylindrical, and other irregularly shaped particles) are all within the meaning of the terms "beads" and "microparticles" as used herein.

[0281] Commercial sources of magnetically sensitive bead preparations include Invitrogen, Life Technologies (Carlsbad, CA, USA), Ademtech (Pessac, France), Chemicell GmbH (Berlin, Germany), Bangs Laboratories, Inc. (Fisher, Indiana) and Seradyn, Inc. (Indianapolis, Indiana). Many commercially available products contain surface functionalizations that can be used to immobilize antibodies (e.g., IgG) on the surface of beads. The functionalization of beads can include carboxyl, amino, or streptavidin-modified magnetically sensitive beads.

[0282] The magnetically sensitive beads are preferably coated with antibodies or antigen-binding portions thereof directed against an analyte that is a cardiovascular marker, such as cardiac troponin I, troponin T, troponin complex, proBNP, NT-proBNP, human chorionic gonadotropin, BNP, creatine kinase, creatine kinase subunit M, creatine kinase subunit B, creatine kinase MB (CK-MB), myoglobin, myosin light chain or a modified fragment thereof, etc. In a preferred embodiment, the cardiovascular marker is troponin I or troponin T. In another preferred embodiment, the cardiovascular marker is proBNP, NT-proBNP.

[0283] In addition, markers for other indications may also be used. Other exemplary analytes include, but are not limited to, beta-HCG, TSH, super hTSH II, TT3, TT4, FT3, FT4, myeloperoxidase, D-dimer, CRP, NGAL, PSA, LH, FSH, galectin-3, prolactin, progesterone, estradiol, DHEA-S, AFP, CA 125II, CA 125, CA 15-3, CA 19-9, CA 19-9XR, CEA, thyroxine (T4), triiodothyronine (T3), T-uptake, Tg, anti-Tg, anti-TPO, ferritin, cortisol, insulin, HBsAg, HCV Ag / Ab combination, HCV core Ag, anti-HCV, AUSAB (anti-HB), CORE, CORE-M, SHBG, iPTH, theophylline, rapamycin, tacrolimus, anti-HAV, anti-HAV IgM, HAVAB, HAVAB-M, HAVAB-M 2.0, HAVAB-G, HAVAB 2.0, HAVAB 2.0Quant, IgM, CMV IgM, CMV IgG, alpha-2-microglobulin, digitoxin, HBe, anti-HBe, HBeAg, HIV l / 2gO, HIV Ag / Ab combination, testosterone, SCC, vitamin B12, folic acid, syphilis, anti-HBc, aibella IgG, aibella IgM, homocysteine, MPO, cytomegalovirus (CMV) IgG affinity, toxoplasma IgG affinity, toxoplasma IgG, toxoplasma IgM, C-peptide, vitamin D, HTLV I / II, total ahCG, progesterone, estrogen, prolactin, myoglobin, tPSA, fPSA, carbamazepine (CBZ), digoxin, gentamicin, NAPA, phenytoin, phenobarbital, valproic acid, vancomycin, procaine, quinidine, tobramycin, methamphetamine (METH), amphetamine (AMPH), barbiturates, benzodiazepines, cannabis, cocaine, methadone, opioids, PCP, acetaminophen, ethanol, salicylates, tricyclic antidepressants, holoTc, anti-CCP, HbA1c, barbs-U, etc. In certain embodiments of the invention, the antibody or its antigen-binding portion is directed to a low-abundance analyte in a sample. The above abbreviations will be familiar to the technician.

[0284] The magnetic immunosensor and method of the present invention preferably also include a second antibody or its antigen binding portion, which is an enzyme-linked antibody or its antigen binding portion, also referred to herein as a signal antibody or its antigen binding portion. In some embodiments, the enzyme-linked antibody or its antigen binding portion is in the form of a liquid reagent, which may also include magnetically sensitive beads used in the present invention, as discussed below. Bead-immobilized antibodies and enzyme-linked antibodies may be monoclonal antibodies, polyclonal antibodies, fragments thereof, and combinations thereof. In addition, one or more antibodies may be labeled with various markers, including radioactive markers, enzymes, chromophores, fluorophores, chemiluminescent species, ionophores, electroactive species, and other markers known in the field of immunoassays. When the second antibody or its antigen binding portion is labeled with an enzyme, the enzyme is preferably ALP, horseradish peroxidase (HRP), or glucose oxidase. In other embodiments, the analyte is labeled with fluorescein, ferrocene, p-aminophenol, or a derivative thereof. In a preferred embodiment, the second antibody or its antigen binding portion is enzyme-linked with horseradish peroxidase (HRP).

[0285] In some embodiments, the magnetically sensitive beads are homogeneously mixed with the sample. In other embodiments, the magnetically sensitive beads may be less homogeneously mixed with the sample; however, one object of the present invention is to optimize the position and concentration of the beads relative to the electrodes. The skilled person will recognize that the magnetically sensitive beads of the present invention can be added to the biological sample prior to introduction into the magnetic immunosensor device, for example as an integral part of a blood collection device or as a standard manual addition step. However, for user convenience and to ensure detection quality, the magnetically sensitive beads are preferably contained within an immunosensor cartridge, for example contained within one or more liquid storage capsules as described above.

[0286] In some embodiments of the present invention, a sample (e.g., a whole blood sample) is collected and then modified by combining with a reagent comprising magnetically sensitive beads. In addition to magnetically sensitive beads, the reagent may also include one or more of the following: beads that reduce leukocyte interference, leukocidal reagents, buffers, salts, surfactants, stabilizers, simple carbohydrates, complex carbohydrates, and various combinations thereof. The reagent may also include an enzyme-labeled antibody or an antigen-binding portion thereof (e.g., the above-mentioned labeled antibody or antigen-binding portion thereof) for the analyte. In some embodiments of the present invention, the additional components required for the determination are included in a single reagent in the form of a composition. In some embodiments of the present invention, at least two additional components required for the determination are included in a single reagent in the form of a composition, and the other components required for the determination are included in separate reagents. In other embodiments of the present invention, the additional components required for the determination are respectively included in separate reagents.

[0287] In some embodiments, magnetically sensitive beads are used to modify a biological sample (e.g., blood) in a first container or location, which is then transferred to a second container or location containing a capture antibody and a signal antibody. In some embodiments, the magnetically sensitive beads are contained in a solution and mixed with the biological sample, and the resulting modified sample is then introduced into a magnetic immunosensor cartridge. For example, a blood sample can be mixed with magnetically sensitive beads to form a modified sample, which is then introduced into the device. In certain embodiments, a magnetic immunosensor device (e.g., a cartridge) includes a capsule containing a liquid containing magnetically sensitive beads, which can be mixed with a biological sample in the device and then processed substantially as described herein to form an assay (e.g., a sandwich assay) for analyte detection.

[0288] Furthermore, any immunoassay format known in the art can be modified to include the magnetically sensitive beads of the present invention, for example, by adding the beads during a sample pretreatment step. Pretreatment can be accomplished, for example, by incorporating the beads into a blood collection device, into a separate container, or can be performed by incorporating the beads into the immunoassay device itself as part of the assay method.

[0289] In some embodiments of the present invention, beads are movable and therefore can interact with analytes. After binding with the analyte of interest, magnetic force is used to concentrate the beads (at the electrode or at a position separated from the electrode space) for washing, and then the beads are concentrated at the electrode for measurement. According to the present invention, an advantage of using movable beads is that their movement in the sample or fluid accelerates the binding reaction, making the capture step of the assay faster.

[0290] In some embodiments of the invention, additives may be included in the magnetic immunosensor device or used in conjunction with the assay. In some embodiments, an anticoagulant may be added. For example, in the case where the sample is not collected in a heparinized tube or is not properly mixed in a heparinized tube, heparin may be added to improve performance. Any suitable amount of heparin may be added so that fresh, non-heparinized blood remains non-coagulated during the assay cycle of the cartridge (usually in the range of 2 to 20 minutes). In other embodiments, one or more of proclin, DEAE-dextran, tris buffer, and lactitol may be added as a reagent stabilizer. In other embodiments, a surfactant such as polysorbate 20 (also known as 20) to reduce the binding of proteins to plastics, which is a preferred material for the cartridge housing of the magnetic immunosensor device. The addition of surfactants also promotes uniform coating of reagents on the plastic surface and minimizes crystallization of sugars (e.g., lactitol). In other embodiments of the invention, antimicrobial agents or biocides (e.g., sodium azide) may be added to inhibit bacterial growth.

[0291] Computer methods

[0292] The above methods can be performed in combination with one another and in a variety of different orders or multiple times, depending on the needs of a given diagnostic test. One method does not need to be completed before performing another method.

[0293] The described method can be implemented by a diagnostic system using computer executable instructions. A computer program product or a computer readable medium may contain or store computer executable instructions. A computer program product or a computer readable medium may include a hard drive, a flash memory, a read-only memory (ROM), a CD, a DVD, a cache, a random access memory (RAM), and / or any other storage medium in which information may be stored for any period of time (e.g., an extended period of time, permanent, transient, temporary buffering, and / or cached information). A computer program may include computer executable instructions. A computer readable medium may be a tangible or non-temporary computer readable medium. The term "computer readable" encompasses "machine readable".

[0294] Therefore, a computer program is also disclosed, comprising computer executable instructions, which, when executed by a diagnostic system, cause the diagnostic system to perform any of the above methods.

[0295] Example

[0296] Example 1 - Dispersion of beads on electrodes using magnet actuation to enhance signal response

[0297] Human pooled plasma (Lit-Heparin) supplemented with 625 ng / ml analyte (recombinant NT-pro-BNP) was measured using standard procedures. Magnetic particles (1 um epoxy beads) coated with capture antibodies or their antigen-binding portions were mixed with plasma samples and sample diluent (25 mM aqueous TBS containing bovine serum albumin (5%), calcium chloride (20 mM), magnesium chloride (20 mM), Proclin 300 (0.05%) and Tween 20 (0.1%)), and detection antibodies labeled with horseradish peroxidase (HRP).

[0298] The reaction mixture was incubated at room temperature in a test tube for 2 minutes, and then the magnetic particles were removed by a magnetic field and washed with a measurement wash buffer containing a PBS solution (10 mM) of Tween-20 at a standard concentration. The washed magnetic particles were driven in the box at a specific flow rate (2 μl / sec) and positioned on the electrode.

[0299] A magnetic field (0.4 Tesla) was applied by magnet actuation, and 12 switching operations were performed and compared with the magnetic field applied without magnet actuation. A 3,3′,5,5′-tetramethylbenzidine (TMB) solution was introduced into the electrode chamber. The measured response (current after 60 s chronoamperometry at -50 mV with resistance (IR) compensation) recorded for each sample was plotted to compare the signals obtained with and without actuation ( Figure 1 ).like Figure 1 As shown, the signal of this assay was enhanced by 1.5-fold using the optimized method.

[0300] Example 2 - Washing with and without magnet actuation - Optimizing washing of bead assays using magnet actuation

[0301] Human plasma (EDTA) containing zero analyte was measured in parallel using the standard procedure in a flow cell format, where only the magnet actuation process was varied.

[0302] The same wash volume (470 μl) was tested under standardized assay conditions. Plasma samples were mixed with sample diluent containing detection antibody labeled with horseradish peroxidase (HRP) at a 1:1 ratio and mixed with magnetic particles coated with capture antibody. The reaction mixture was incubated in the fluidic channel for 5 minutes at 30°C, and then the magnetic particles were removed by a magnetic field and washed with assay wash buffer (only the use or not of magnet actuation during the wash process was changed).

[0303] The washed magnetic particles were resuspended and transported to a clean flow cell where the beads were pulled down onto the 2.5 mm electrode and the detection solution introduced. The assay response currents recorded for zero and 100 ng / L analyte samples for each wash process (varying magnet actuation) at -50 mV using chronoamperometry showed that the use of controlled mechanical magnet actuation during the wash process reduced the non-specific binding of the assay defined by the background measurement when zero analyte was present ( Figure 2 ). Figure 2 It was shown that the background signal was reduced to 1 / 4 using the improved washing method.

[0304] Example 3 - Reducing wash volumes by magnet actuation process - Optimizing bead assay washes using magnet actuation

[0305] Human plasma (EDTA) containing zero analyte and the same plasma supplemented with 100 ng / L analyte were measured in parallel using standard procedures in a flow cell format, with only the wash volume being varied.

[0306] The same actuation method was used under standardized assay conditions. Plasma samples were mixed with sample diluent containing detection antibodies labeled with horseradish peroxidase (HRP) in a 1:1 ratio and mixed with magnetic particles coated with capture antibodies. The reaction mixture was incubated in the fluid channel at 30°C for 5 minutes, and then the magnetic particles were removed by a magnetic field and washed with assay wash buffer by successive mechanical magnet actuations (only the total wash volume used was changed to 470 μl, 260 μl, 160 μl). The washed magnetic particles were resuspended and transported to a clean flow cell, where the beads were pulled down onto the 2.5 mm electrode and the detection solution was introduced.

[0307] The assay response currents recorded for zero analyte and 100 ng / L analyte samples using chronoamperometry at -50 mV for the same wash process (with different total wash volumes) show that the use of controlled mechanical magnet actuation during the wash process not only reduces the background response but also reduces the volume required for the wash assay from 470 μl to 160 μl ( Figure 3 ). Figure 3 It was shown that with the improved washing method, the wash volume was reduced to 1 / 3. This allows a smaller volume of wash liquid to be stored on the cartridge and thereby reduces the required cartridge footprint. Smaller cartridges are more suitable for use in point-of-care testing devices, so this means that the method is an improved method for use with such devices.

[0308] Example 4 - Improving Signal Using Magnet Actuation - Optimizing Signal-to-Noise Ratio Using Magnet Actuation

[0309] Human plasma (EDTA) containing zero analyte and the same sample supplemented with 50 ng / L analyte were used in parallel and measured in parallel using the standard procedure in a flow cell format, where only the magnet actuation process was changed before the measurement.

[0310] The same reagents were tested under standardized assay conditions. Plasma samples were mixed with sample diluent containing detection antibodies labeled with horseradish peroxidase (HRP) at a 1:1 ratio and mixed with magnetic particles coated with capture antibodies. The reaction mixture was incubated in the fluidic channel at 30°C for 5 minutes, and then the magnetic particles were removed by a magnetic field and washed with assay wash buffer.

[0311] The washed magnetic particles were resuspended and transported to a clean flow cell where the beads were pulled down onto a 2.5 mm electrode and the detection solution introduced prior to reading (we compared with and without magnet actuation). The assay response currents recorded at -50 mV for zero and 50 ng / L analyte samples with and without magnet actuation using chronoamperometry showed that the use of controlled mechanical magnet actuation increased specific labeling and reduced nonspecific interactions, which was reflected in improved assay performance ( Figure 4 ).

[0312] Example 5 - Bead Resuspension Using an Air-Liquid Interface - Optimizing Bead Resuspension Using an Air-Liquid Interface

[0313] Human plasma (EDTA) containing zero analyte was supplemented with 100 ng / L analyte and measured in parallel using the standard procedure in a flow cell format, where only the number of air-liquid interfaces used was varied.

[0314] The same reagents were tested under standardized assay conditions. Plasma samples were mixed with sample diluent containing detection antibodies labeled with horseradish peroxidase (HRP) at a 1:1 ratio and mixed with magnetic particles coated with capture antibodies. The reaction mixture was incubated in the fluidic channel at 30°C for 5 minutes, and then the magnetic particles were removed by a magnetic field and washed with assay wash buffer. The washed magnetic particles were resuspended and transported to a clean flow cell, varying the number of air-liquid interfaces used to transfer the beads.

[0315] If one interface is used during bead resuspension and transfer, the flow cell is emptied with air flow, and the beads are resuspended and transferred to the sensor using a single volume of wash buffer. If two interfaces are used during bead resuspension and transfer, the flow cell is emptied with air flow, and the beads are resuspended and transferred to the sensor using a first volume and a second volume of wash buffer. An air flow is used to create an air-liquid interface between the first volume and the second volume of wash buffer.

[0316] The beads were pulled down onto the 2.5 mm electrode and the detection solution introduced. The assay response currents recorded at -50 mV using chronoamperometry for zero and 100 ng / L analyte samples using each interface iteration (different interface) showed that increasing the number of interfaces enhanced the assay signal, which was reflected in the increase in the number / dispersion of beads on the electrode surface ( Figure 5 ).

[0317] Example 6 - Establishing the ability to measure TMB precipitated on magnetic beads using DPV

[0318] Troponin-free serum was used as experimental matrix, and standard experimental procedures were followed.

[0319] The magnetic particles coated with the capture antibody were mixed with troponin-free serum and sample diluent (25 mM aqueous TBS, containing bovine serum albumin (5%), sodium chloride (400 mM)), and detection antibody labeled with horseradish peroxidase (HRP). The reaction mixture was incubated in the well plate at 25°C for 5 minutes, and then the magnetic particles were removed by a magnetic field and washed with assay wash buffer PBS-T 0.1%.

[0320] The washed magnetic particles were resuspended in the wells and the 3,3′,5,5′-tetramethylbenzidine (TMB) solution to be precipitated was introduced and incubated for 1 minute. Subsequently, the TMB was removed by pulling the magnetic particles at the bottom of the well plate using a magnet. The beads were then resuspended and loaded into separate wells and pulled down to the electrode surface. The assay response at two concentrations of 0 and 50 ng / ml was recorded using differential pulse voltammetry (DPV) peak height signals and the signal-to-noise ratio (S / N) ( Figure 7 ). These results confirm that the TMB substrate has been precipitated on the magnetic beads.

[0321] According to the proposed method, TMB precipitation on magnetic beads allows the detection reaction to be terminated by additional washing and optional resuspension steps. The additional washing steps improve the signal-to-noise ratio by reducing the background without significantly affecting the detection signal.

[0322] Example 7 - Multiplex Assays

[0323] The magnetic beads may be coated with antibodies against two or more different target analytes (e.g. NT-proBNP and troponin). The sample is mixed (or premixed) with a diluent and then incubated with a mixture of different second (i.e. detection) antibodies against each target analyte. For example, for the first analyte (e.g. NT-proBNP), the detection antibody may be labeled with alkaline phosphatase, while for the second analyte (e.g. troponin), the detection antibody may be labeled with HRP. The solution is then mixed with magnetic particles and incubated at a specific temperature (as described herein) for a certain period of time (as described herein). The beads are then captured on the electrode surface using a magnet.

[0324] The beads containing the analyte and the labeled second antibody will be washed by resuspending and pulled down. After washing, two substrates are added to the beads in sequence: 1) A precipitating substrate for the first enzyme (e.g., an alkaline phosphatase substrate such as BCIP / NBT) is added and incubated for a certain period of time. This will react and deposit a precipitate locally in the area of ​​the beads where the first analyte (e.g., NT-proBNP) is captured. The beads are then washed to remove excess substrate, leaving only the precipitate formed on the beads. Subsequently, a suitable substrate for the second enzyme is added (e.g., an HRP substrate such as TMB to be precipitated), and similar to the first enzyme substrate, it will react and precipitate only in the area where the second analyte (e.g., troponin) is captured. The beads will undergo a final wash and then be transferred to the detection electrode.

[0325] Then, use electrochemical detection technology (preferably differential pulse voltammetry, DPV) and each precipitation reagent will obtain two characteristic peaks because they have different electrochemical characteristics. The signal generated is proportional to the amount of each analyte. In a similar manner, beads can be coated with a variety of precipitation electrochemical media with unique electrochemical characteristics to provide more multiple options for parallel detection of different analytes.

[0326] The present invention is further described by the following numbered embodiments:

[0327] 1) A method for measuring an analyte of interest in a biological sample, comprising:

[0328] The biological sample is combined with a composition comprising:

[0329] magnetically sensitive beads conjugated to a first antibody or antigen binding portion thereof, the first antibody or antigen binding portion thereof being capable of binding the analyte of interest; and

[0330] a second antibody or antigen binding portion thereof conjugated to an enzyme, the second antibody or antigen binding portion thereof being capable of binding to the analyte of interest;

[0331] The magnetic sensitive beads are retained on the electrodes using a magnetic field;

[0332] contacting the magnetically sensitive beads with a substrate for the enzyme, wherein the enzyme substrate is converted by the enzyme into an electroactive molecule; and

[0333] Electrochemical measurements were obtained using the electrodes.

[0334] 2) A method for measuring one or more analytes of interest in a biological sample, comprising:

[0335] The biological sample is combined with a composition comprising:

[0336] magnetically sensitive beads conjugated to one or more antibodies or antigen binding portions thereof, wherein each antibody or antigen binding portion thereof is capable of binding one of said analytes of interest; and

[0337] one or more second antibodies or antigen binding portions thereof conjugated to an enzyme, wherein each second antibody or antigen binding portion thereof is capable of binding to one of the analytes of interest;

[0338] The magnetic sensitive beads are retained on the electrodes using a magnetic field;

[0339] contacting the magnetically sensitive beads with one or more enzyme substrates, wherein the enzyme substrates are converted by the enzymes into electroactive molecules; and

[0340] Electrochemical measurements were obtained using the electrodes.

[0341] 3) A method according to embodiment 2, wherein the method is capable of detecting at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 different analytes of interest.

[0342] 4) The method according to embodiment 2 or embodiment 3, wherein each magnetically sensitive bead is conjugated to a plurality of different antibodies or antigen binding portions thereof, wherein each antibody or antigen binding portion thereof is capable of binding to one of the analytes of interest.

[0343] 5) A method according to embodiment 2 or embodiment 3, wherein the magnetically sensitive beads comprise different groups of magnetically sensitive beads, wherein each group of magnetically sensitive beads is conjugated to a different antibody or its antigen-binding portion, wherein each antibody or its antigen-binding portion is capable of binding to one of the analytes of interest.

[0344] 6) The method for measuring an analyte of interest in a biological sample according to any preceding embodiment, wherein the enzyme substrate is converted into a soluble electroactive molecule by the enzyme at the electrode.

[0345] 7) The method for measuring an analyte of interest in a biological sample according to any one of embodiments 1 to 5, wherein the enzyme substrate is converted by the enzyme into an electroactive molecule precipitated on the magnetically sensitive beads.

[0346] 8) The method for measuring an analyte of interest in a biological sample according to any of the preceding embodiments, further comprising:

[0347] The combined biological sample and composition are incubated to allow the one or more first antibodies and / or the one or more second antibodies to bind to the analyte of interest.

[0348] 9) The method for measuring an analyte of interest in a biological sample according to any of the preceding embodiments, further comprising:

[0349] Using a magnetic field to retain the magnetically sensitive beads in a fixed position; and

[0350] Wash the magnetically sensitive beads.

[0351] 10) A method according to embodiment 9, wherein the fixed position is located at an electrode.

[0352] 11) According to the method of embodiment 9, the fixed position is a position spatially far away from the electrode, optionally wherein the spatially far away position is a blank electrode or a non-functional electrode.

[0353] 12) The method for measuring an analyte of interest in a biological sample according to any one of embodiments 1 to 9, further comprising:

[0354] retaining the magnetically sensitive bead in the first position using a magnetic field; and

[0355] The magnetically sensitive beads are washed by adjusting the magnetic field to retain the magnetically sensitive beads in the second position.

[0356] 13) The method for measuring an analyte of interest in a biological sample according to any preceding embodiment, wherein the magnetic field is generated by a fixed magnet.

[0357] 14) The method for measuring an analyte of interest in a biological sample according to any preceding embodiment, wherein the magnetic field is generated by an electromagnet.

[0358] 15) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 12 to 14, wherein the magnetic field is adjusted by physically actuating a magnet.

[0359] 16) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 12 to 14, wherein the magnetic field is adjusted by controlling the current in the electromagnet.

[0360] 17) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 9 to 15, wherein the magnetic field is located within a microfluidic device having a flow conduit, and wherein the magnetic field is adjusted by actuating a magnet in a direction perpendicular to the flow direction within the flow conduit.

[0361] 18) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 9 to 14 or 16, wherein the magnetic field is located within a microfluidic device having a flow conduit, and wherein the magnetic field is adjusted by controlling the current in an electromagnet.

[0362] 19) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 12 to 18, wherein the magnetically sensitive beads are moved between the first position and the second position at least 20 times, for example at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 11 times, at least 12 times, at least 13 times, at least 14 times, at least 15 times, at least 16 times, at least 17 times, at least 18 times or at least 19 times.

[0363] 20) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 12 to 18, wherein the magnetically sensitive bead is moved between the first position and the second position 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 11 times, 12 times, 13 times, 14 times, 15 times, 16 times, 17 times, 18 times, 19 times or 20 times, preferably 12 times.

[0364] 21) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 12 to 20, wherein the magnetic field is adjusted so that the magnetically sensitive beads move periodically between the first position and the second position.

[0365] 22) The method for measuring an analyte of interest in a biological sample according to embodiment 21, wherein the time interval between the magnetically sensitive bead being in the first position and being in the second position is about 0.01 second to about 5 seconds, about 0.05 second to about 5 seconds, about 0.1 second to about 5 seconds, about 0.2 second to about 5 seconds, about 0.3 second to about 5 seconds, about 0.4 second to about 5 seconds, about 0.5 second to about 5 seconds, about 1 second to about 5 seconds, about 2 seconds to about 5 seconds, about 3 seconds to about 5 seconds, about 4 seconds to about 5 seconds, about 0.01 second to about 4 seconds, about 0.05 second to about 4 seconds, about 0.1 second to about 4 seconds, From about 0.2 seconds to about 4 seconds, from about 0.3 seconds to about 4 seconds, from about 0.4 seconds to about 4 seconds, from about 0.5 seconds to about 4 seconds, from about 1 second to about 4 seconds, from about 2 seconds to about 4 seconds, from about 3 seconds to about 4 seconds, from about 0.01 seconds to about 3 seconds, from about 0.05 seconds to about 3 seconds, from about 0.1 seconds to about 3 seconds, from about 0.2 seconds to about 3 seconds, from about 0.3 seconds to about 3 seconds, from about 0.4 seconds to about 3 seconds, from about 0.5 seconds to about 3 seconds, from about 1 second to about 3 seconds, from about 2 seconds to about 3 seconds, from about 0.01 seconds to about 2 seconds, from about 0.05 seconds to about 2 seconds, from about 0.1 seconds to about 2 seconds, from about 0.2 seconds to about 2 seconds, 0.3 seconds to about 2 seconds, about 0.4 seconds to about 2 seconds, about 0.5 seconds to about 2 seconds, about 1 second to about 2 seconds, about 0.01 seconds to about 1 second, about 0.05 seconds to about 1 second, about 0.1 seconds to about 1 second, about 0.2 seconds to about 1 second, about 0.3 seconds to about 1 second, about 0.4 seconds to about 1 second, about 0.5 seconds to about 1 second, about 0.01 seconds to about 0.5 seconds, about 0.05 seconds to about 0.5 seconds, about 0.1 seconds to about 0.5 seconds, about 0.2 seconds to about 0.5 seconds, about 0.3 seconds to about 0.5 seconds, about 0.4 seconds to about 0.5 seconds, about 0.01 seconds to about 0.4 seconds , about 0.05 seconds to about 0.4 seconds, about 0.1 seconds to about 0.4 seconds, about 0.2 seconds to about 0.4 seconds, about 0.3 seconds to about 0.4 seconds, about 0.01 seconds to about 0.3 seconds, about 0.05 seconds to about 0.3 seconds, about 0.1 seconds to about 0.3 seconds, about 0.2 seconds to about 0.3 seconds, about 0.01 seconds to about 0.2 seconds, about 0.05 seconds to about 0.2 seconds, about 0.1 seconds to about 0.2 seconds, about 0.01 seconds to about 0.1 seconds, about 0.05 seconds to about 0.1 seconds, about 0.01 seconds to about 0.05 seconds, preferably about 3 seconds to about 5 seconds, and more preferably about 4 seconds.

[0366] 23) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 9 to 22, wherein the magnetically sensitive beads are washed with a washing solution and / or air.

[0367] 24) A method for measuring an analyte of interest in a biological sample according to embodiment 23, wherein the magnetically sensitive beads are washed sequentially and separately using a washing solution and air.

[0368] 25) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 9 to 24, wherein the magnetic sensitive beads are washed alternately with a washing solution and air at least twice, at least three times, at least four times or at least five times, preferably wherein the magnetic sensitive beads are washed alternately with a washing solution and air twice.

[0369] 26) A method for measuring an analyte of interest in a biological sample according to any preceding embodiment, wherein the biological sample is diluted prior to binding to the magnetically sensitive beads.

[0370] 27) The method for measuring an analyte of interest in a biological sample according to any preceding embodiment, wherein the electrode is a carbon ink electrode.

[0371] 28) A method for measuring an analyte of interest in a biological sample according to any preceding embodiment, wherein the analyte of interest is brain natriuretic peptide or N-terminal pro-BNP.

[0372] 29) The method for measuring an analyte of interest in a biological sample according to any one of embodiments 1 to 28, wherein the analyte of interest is cardiac troponin or cardiac troponin subunit I (cTnI).

[0373] 30) A method for measuring analytes of interest in a biological sample according to any one of embodiments 2 to 27, wherein one or more analytes of interest are selected from the list consisting of brain natriuretic peptide, N-terminal pro-BNP, cardiac troponin and cardiac troponin subunit I (cTnI).

[0374] 31) A method for measuring analytes of interest in a biological sample according to any one of embodiments 2 to 27 or 30, wherein the one or more analytes of interest are N-terminal pro BNP and cardiac troponin subunit I (cTnI).

[0375] 32) The method for measuring an analyte of interest in a biological sample according to any preceding embodiment, wherein the enzyme is horseradish peroxidase (HRP).

[0376] 33) The method for measuring an analyte of interest in a biological sample according to any one of embodiments 1 to 31, wherein the enzyme is alkaline phosphatase (ALP).

[0377] 34) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 2 to 33, wherein at least one of the one or more second antibodies or their antigen-binding portions is conjugated to horseradish peroxidase (HRP) and at least one of the one or more second antibodies or their antigen-binding portions is conjugated to alkaline phosphatase (ALP).

[0378] 35) A method for measuring an analyte of interest in a biological sample according to any of the preceding embodiments, wherein the substrate of the enzyme is selected from the list consisting of: 3,3',5,5'-tetramethylbenzidine (TMB), 2,2'-azinobis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS), o-phenylenediamine dihydrochloride (OPD), p-nitrophenyl phosphate (PNPP) and BCIP / NBT (a combination of BCIP (5-bromo-4-chloro-3-indolyl phosphate) and NBT (nitro blue tetrazolium)).

[0379] 36) A method for measuring an analyte of interest in a biological sample according to embodiment 35, wherein the product of the enzymatic reaction is precipitated, optionally wherein the product is precipitated onto magnetically sensitive beads.

[0380] 37) A method for measuring an analyte of interest in a biological sample according to embodiment 35, wherein the substrate is 3,3',5,5'-tetramethylbenzidine (TMB) and the product of the enzymatic reaction is precipitated, optionally wherein the product is precipitated onto magnetically sensitive beads.

[0381] 38) A method for measuring an analyte of interest in a biological sample according to embodiment 35, wherein the substrate is BCIP / NBT (a combination of BCIP (5-bromo-4-chloro-3-indolyl phosphate) and NBT (nitro blue tetrazolium), and the product of the enzymatic reaction is precipitated, optionally wherein the product is precipitated onto magnetically sensitive beads.

[0382] 39) A method for measuring an analyte of interest in a biological sample according to any preceding embodiment, wherein the electrochemical measurement is indicative of the concentration or amount of the analyte of interest.

[0383] 40) A method for measuring an analyte of interest in a biological sample according to embodiment 39, wherein the concentration or amount of the analyte of interest is determined by comparison with a reference solution.

[0384] 41) The method for measuring an analyte of interest in a biological sample according to any of the preceding embodiments, wherein the electrochemical measurement is amperometric measurement, voltammetric measurement, potentiometric measurement, impedance measurement or electrochemical impedance spectroscopy measurement, preferably chronoamperometric measurement.

[0385] 42) The method of measuring an analyte of interest in a biological sample according to any preceding embodiment, wherein the electrochemical measurement is differential pulse voltammetry (DPV).

[0386] 43) A method according to any preceding embodiment, wherein the measuring method is a sandwich immunoassay.

[0387] 44) A method according to any preceding embodiment, wherein at least 50% (e.g., at least 60%, at least 70%, at least 80%, at least 90% or at least 95%) of the beads, measured as wt %, remain on the surface of the electrode.

[0388] 45) A method for measuring an analyte of interest in a biological sample, comprising:

[0389] The biological sample is combined with a composition comprising:

[0390] magnetically sensitive beads conjugated to a first antibody or antigen binding portion thereof, the first antibody or antigen binding portion thereof being capable of binding the analyte of interest; and

[0391] a second antibody or antigen binding portion thereof conjugated to an enzyme, the second antibody or antigen binding portion thereof being capable of binding to the analyte of interest;

[0392] The magnetic sensitive beads are retained on the electrodes using a magnetic field;

[0393] contacting the magnetically sensitive beads with a substrate for the enzyme, wherein the enzyme substrate is converted by the enzyme into a precipitated electroactive molecule; and

[0394] Electrochemical measurements were obtained using the electrodes.

[0395] 46) A method for measuring one or more analytes of interest in a biological sample, comprising:

[0396] The biological sample is combined with a composition comprising:

[0397] magnetically sensitive beads conjugated to one or more antibodies or antigen binding portions thereof, wherein each antibody or antigen binding portion thereof is capable of binding one of said analytes of interest; and

[0398] one or more second antibodies or antigen binding portions thereof conjugated to an enzyme, wherein each second antibody or antigen binding portion thereof is capable of binding to one of the analytes of interest;

[0399] The magnetic sensitive beads are retained on the electrodes using a magnetic field;

[0400] contacting the magnetically sensitive beads with one or more enzyme substrates, wherein the enzyme substrates are converted by the enzymes into precipitated electroactive molecules; and

[0401] Electrochemical measurements were obtained using the electrodes.

[0402] 47) A method according to embodiment 46, wherein the method is capable of detecting at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 different analytes of interest.

[0403] 48) A method according to any one of embodiments 45 or 46, wherein the electroactive molecules are precipitated onto magnetically sensitive beads.

[0404] 49) A method according to any one of embodiments 45 to 47, wherein the one or more analytes of interest are N-terminal pro BNP and cardiac troponin subunit I (cTnI).

[0405] 50) The method for measuring an analyte of interest in a biological sample according to any one of embodiments 45 to 48, wherein the enzyme is horseradish peroxidase (HRP).

[0406] 51) The method for measuring an analyte of interest in a biological sample according to any one of embodiments 45 to 48, wherein the enzyme is alkaline phosphatase (ALP).

[0407] 52) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 46 to 49, wherein at least one of the one or more second antibodies or their antigen-binding portions is conjugated to horseradish peroxidase (HRP) and at least one of the one or more second antibodies or their antigen-binding portions is conjugated to alkaline phosphatase (ALP).

[0408] 53) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 45 to 51, wherein the substrate of the enzyme is selected from the list consisting of: 3,3',5,5'-tetramethylbenzidine (TMB), 2,2'-azinobis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS), o-phenylenediamine dihydrochloride (OPD), p-nitrophenyl phosphate (PNPP) and BCIP / NBT (a combination of BCIP (5-bromo-4-chloro-3-indolyl phosphate) and NBT (nitro blue tetrazolium)).

[0409] 54) A method according to any of the preceding embodiments, wherein the magnetically sensitive beads and the biological sample are incubated at a temperature of 10°C to 50°C, optionally 15°C to 45°C, optionally 20°C to 40°C, optionally 20°C to 30°C, optionally 25°C to 35°C, optionally 25°C, optionally 30°C, or optionally 40°C.

[0410] 55) A composition comprising: magnetically sensitive beads conjugated to a first antibody or an antigen binding portion thereof, the first antibody or the antigen binding portion thereof being capable of binding an analyte of interest; and

[0411] A second antibody or antigen binding portion thereof conjugated to an enzyme, the second antibody or antigen binding portion thereof being capable of binding to the analyte of interest.

[0412] 56) A composition comprising: magnetically sensitive beads conjugated to one or more antibodies or antigen-binding portions thereof, wherein each antibody or antigen-binding portion thereof is capable of binding an analyte of interest; and

[0413] One or more second antibodies or antigen binding portions thereof conjugated to an enzyme, wherein each second antibody or antigen binding portion thereof is capable of binding to one of the analytes of interest.

[0414] 57) A composition according to embodiment 56, wherein each magnetically sensitive bead is conjugated to a plurality of different antibodies or antigen binding portions thereof, wherein each antibody or antigen binding portion thereof is capable of binding to one of the analytes of interest.

[0415] 58) A composition according to embodiment 56, wherein the magnetically sensitive beads include different groups of magnetically sensitive beads, wherein each group of magnetically sensitive beads is conjugated to a different antibody or its antigen binding portion, wherein each antibody or its antigen binding portion is capable of binding to one of the analytes of interest.

[0416] 59) A composition according to any one of embodiments 55 to 58, wherein the composition is capable of detecting at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 different analytes of interest.

[0417] 60) A composition according to any one of embodiments 55 to 59, wherein the analyte of interest is brain natriuretic peptide or N-terminal pro-BNP.

[0418] 61) A composition according to any one of embodiments 55 to 59, wherein the analyte of interest is cardiac troponin or cardiac troponin subunit I (cTnI).

[0419] 62) A composition according to any one of embodiments 55 to 61, wherein the one or more analytes of interest are N-terminal pro BNP and cardiac troponin subunit I (cTnI).

[0420] 63) A composition according to any one of embodiments 55 to 62, wherein the enzyme is horseradish peroxidase (HRP) or alkaline phosphatase (ALP).

[0421] 64) A composition according to any one of embodiments 55 to 63, wherein at least one of the one or more second antibodies or antigen-binding portions thereof is conjugated to horseradish peroxidase (HRP), and at least one of the one or more second antibodies or antigen-binding portions thereof is conjugated to alkaline phosphatase (ALP).

[0422] 65) A composition according to any one of embodiments 55 to 64, wherein the substrate of the enzyme is selected from the list consisting of: 3,3',5,5'-tetramethylbenzidine (TMB), 2,2'-azinobis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS), o-phenylenediamine dihydrochloride (OPD), p-nitrophenyl phosphate (PNPP) and BCIP / NBT (a combination of BCIP (5-bromo-4-chloro-3-indolyl phosphate) and NBT (nitro blue tetrazolium)).

[0423] 66) A kit for performing the method according to any one of embodiments 1 to 54, comprising:

[0424] magnetically sensitive beads;

[0425] An immunoassay device comprising an electrode; and

[0426] A magnet located near the chip is used to retain the magnetically sensitive beads near the electrodes.

[0427] 67) The kit according to embodiment 66 further includes a device for retaining the magnetically sensitive beads at a separate location spatially away from the electrodes.

[0428] 68) A kit according to embodiment 67, wherein the means for retaining the magnetically sensitive beads at a separate location spatially away from the electrode is the same magnet used to retain the magnetically sensitive beads near the electrode.

[0429] 69) A kit according to embodiment 67, wherein the device for retaining the magnetically sensitive beads at a separate location spatially away from the electrode is a second magnet configured to retain the magnetically sensitive beads at a separate location spatially away from the electrode.

[0430] 70) A kit according to any one of embodiments 66 to 69, wherein the magnet is a permanent magnet or an electromagnet.

[0431] 71) A method for measuring an analyte of interest in a biological sample, comprising:

[0432] The biological sample is combined with a composition comprising:

[0433] magnetically sensitive beads conjugated to a first antibody or antigen binding portion thereof, the first antibody or antigen binding portion thereof being capable of binding the analyte of interest; and

[0434] a second antibody or antigen binding portion thereof conjugated to an enzyme, the second antibody or antigen binding portion thereof being capable of binding to the analyte of interest;

[0435] The magnetic sensitive beads are retained on the electrodes using a magnetic field;

[0436] contacting the magnetically sensitive beads with a substrate for the enzyme, wherein the enzyme substrate is converted by the enzyme into a precipitated electroactive molecule; and

[0437] An electrochemical measurement is obtained using the electrode, wherein the biological sample and the composition are combined at a location spatially remote from the electrode, optionally wherein the spatially remote location is a blank electrode or a non-functional electrode.

[0438] 72) A method for measuring an analyte of interest in a biological sample, comprising:

[0439] The biological sample is combined with a composition comprising:

[0440] magnetically sensitive beads conjugated to one or more antibodies or antigen binding portions thereof, wherein each antibody or antigen binding portion thereof is capable of binding one of said analytes of interest; and

[0441] one or more second antibodies or antigen binding portions thereof conjugated to an enzyme, wherein each second antibody or antigen binding portion thereof is capable of binding to one of the analytes of interest;

[0442] The magnetic sensitive beads are retained on the electrodes using a magnetic field;

[0443] contacting the magnetically sensitive beads with one or more enzyme substrates, wherein the enzyme substrates are converted by the enzymes into precipitated electroactive molecules; and

[0444] An electrochemical measurement is obtained using the electrode, wherein the biological sample and the composition are combined at a location spatially remote from the electrode, optionally wherein the spatially remote location is a blank electrode or a non-functional electrode.

[0445] 73) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 71 or 72, wherein the magnetically sensitive beads are contacted with a substrate for one or more enzymes at a location spatially distant from the electrode.

[0446] 74) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 71 to 73, wherein the magnetically sensitive beads are washed with a washing solution and / or air at a location spatially distant from the electrode.

[0447] 75) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 71 to 74, wherein the magnetically sensitive beads are washed sequentially and separately using a washing solution and air at a location spatially distant from the electrode.

[0448] 76) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 71 to 75, wherein the magnetically sensitive beads are washed alternately with a washing solution and air at a position spatially away from the electrode at least twice, at least three times, at least four times or at least five times, preferably wherein the magnetically sensitive beads are washed alternately with a washing solution and air at a position spatially away from the electrode twice.

[0449] 77) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 71 to 76, wherein the biological sample and the composition are combined at a location spatially away from the electrode and then the magnetically sensitive beads are moved to the electrode to obtain an electrochemical measurement.

[0450] 78) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 71 to 77, wherein the magnetically sensitive beads are contacted with a substrate of one or more enzymes at a location spatially away from the electrode and then moved to the electrode to obtain an electrochemical measurement.

[0451] 79) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 71 to 78, wherein the magnetically sensitive beads are contacted with a substrate of one or more enzymes at a location spatially away from the electrode and then moved to the electrode to obtain an electrochemical measurement.

[0452] 80) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 71 to 79, wherein:

[0453] (i) combining the biological sample and the composition at a location spatially remote from the electrode; and / or

[0454] (ii) retaining the magnetically sensitive beads at a location spatially distant from the electrode and washing them with a washing solution and / or air,

[0455] The magnetically sensitive beads are then moved to the electrodes to obtain electrochemical measurements, optionally wherein the spatially distant location used for combining the biological sample and the composition is the same as the spatially distant location used for washing.

[0456] 81) A method for measuring an analyte of interest in a biological sample according to any one of embodiments 71 to 80, wherein:

[0457] (i) combining the biological sample and the composition at a location spatially remote from the electrode,

[0458] (ii) contacting the magnetically sensitive beads with substrates for one or more enzymes at a location spatially remote from the electrodes; and / or

[0459] (iii) retaining the magnetically sensitive beads at a location spatially distant from the electrode and washing them with a washing solution and / or air,

[0460] The magnetically sensitive beads are then moved to the electrodes to obtain electrochemical measurements, optionally wherein the spatially distant locations used to combine the biological sample and the composition, the spatially distant locations used for washing, and / or the spatially distant locations used to contact the magnetically sensitive beads with substrates for one or more enzymes are the same.

Claims

1. A method for measuring an analyte of interest in a biological sample, comprising: The biological sample is combined with a composition comprising: magnetically sensitive beads conjugated to a first antibody or antigen binding portion thereof, the first antibody or antigen binding portion thereof being capable of binding the analyte of interest; and a second antibody or antigen binding portion thereof conjugated to an enzyme, the second antibody or antigen binding portion thereof being capable of binding the analyte of interest; retaining the magnetically sensitive beads on the electrodes using a magnetic field; contacting the magnetically sensitive beads with a substrate for the enzyme, wherein the enzyme substrate is converted into an electroactive molecule by the enzyme; and Electrochemical measurements were obtained using the electrodes.

2. The method for measuring an analyte of interest in a biological sample according to claim 1, wherein: The enzyme substrate is converted by the enzyme to a soluble electroactive molecule at the electrode.

3. The method for measuring an analyte of interest in a biological sample according to claim 1, wherein: The enzyme substrate is converted by the enzyme into an electroactive molecule precipitated on the magnetically sensitive beads.

4. The method of measuring an analyte of interest in a biological sample according to any one of the preceding claims, further comprising: The combined biological sample and the composition are incubated to allow the first antibody and / or the second antibody to bind to the analyte of interest.

5. The method of measuring an analyte of interest in a biological sample according to any one of the preceding claims, further comprising: Using a magnetic field to retain the magnetically sensitive beads in a fixed position; as well as The magnetically sensitive beads are washed.

6. The method according to claim 5, wherein: The fixed position: a. located at the electrode; or b. is a location spatially distant from the electrode, optionally wherein the spatially distant location is a blank electrode or a non-functional electrode.

7. The method for measuring an analyte of interest in a biological sample according to any one of claims 1 to 4, further comprising: retaining the magnetically sensitive bead in the first position using a magnetic field; as well as The magnetically sensitive beads are washed by adjusting the magnetic field to retain the magnetically sensitive beads in the second position.

8. A method for measuring an analyte of interest in a biological sample according to any one of the preceding claims, wherein: The magnetic field is generated by: a. Fixed magnet; or b. Electromagnet.

9. The method for measuring an analyte of interest in a biological sample according to any one of claims 7 or 8, wherein: The magnetic field is adjusted by physically actuating the magnet.

10. A method for measuring an analyte of interest in a biological sample according to any one of the preceding claims, wherein: The magnetic field is located within a microfluidic device having a flow conduit, and wherein the magnetic field is modulated by actuating the magnet in a direction perpendicular to a direction of flow within the flow conduit.

11. The method for measuring an analyte of interest in a biological sample according to any one of claims 7 to 10, wherein: The magnetically sensitive bead moves between the first position and the second position at least 20 times, for example, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 11 times, at least 12 times, at least 13 times, at least 14 times, at least 15 times, at least 16 times, at least 17 times, at least 18 times or at least 19 times.

12. The method for measuring an analyte of interest in a biological sample according to any one of claims 5 to 11, wherein: The magnetically sensitive beads are washed with a washing solution and / or air.

13. The method of measuring an analyte of interest in a biological sample according to claim 12, wherein: The magnetically sensitive beads are washed sequentially and separately using a washing solution and air.

14. The method for measuring an analyte of interest in a biological sample according to any one of claims 5 to 13, wherein: The magnetically sensitive beads are washed alternately with a washing solution and air at least twice, at least three times, at least four times or at least five times, preferably wherein the magnetically sensitive beads are washed alternately with a washing solution and air twice.

15. A method for measuring an analyte of interest in a biological sample according to any one of the preceding claims, wherein: The electrode is a carbon ink electrode.

16. A method for measuring an analyte of interest in a biological sample according to any one of the preceding claims, wherein: The analyte of interest is brain natriuretic peptide or N-terminal pro-BNP.

17. The method for measuring an analyte of interest in a biological sample according to any one of claims 1 to 15, wherein: The analyte of interest is cardiac troponin or cardiac troponin subunit I (cTnI).

18. A method for measuring an analyte of interest in a biological sample according to any one of the preceding claims, wherein: The enzyme is horseradish peroxidase (HRP) or alkaline phosphatase (ALP).

19. A method for measuring an analyte of interest in a biological sample according to any one of the preceding claims, wherein: The substrate of the enzyme is selected from the list consisting of: 3,3',5,5'-tetramethylbenzidine (TMB), 2,2'-azinobis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS), o-phenylenediamine dihydrochloride (OPD), p-nitrophenyl phosphate (PNPP) and BCIP / NBT (a combination of BCIP (5-bromo-4-chloro-3-indolyl phosphate) and NBT (nitro blue tetrazolium)).

20. A method for measuring an analyte of interest in a biological sample according to any one of the preceding claims, wherein: The electrochemical measurement is an amperometric measurement, a voltammetric measurement, a potentiometric measurement, an impedance measurement or an electrochemical impedance spectroscopy measurement, preferably a chronoamperometric measurement.

21. A method according to any one of the preceding claims, wherein: The measuring method is a sandwich immunoassay.

22. A method according to any one of the preceding claims, wherein: At least 50% (eg, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%) of the beads, measured as wt%, remain on the surface of the electrode.

23. A kit for performing the method according to any one of claims 1 to 22, comprising: magnetically sensitive beads; Immunoassay devices including electrodes; as well as A magnet is located near the chip, the magnet being used to retain the magnetically sensitive beads near the electrodes.

24. The kit of claim 23, further comprising means for retaining the magnetically sensitive beads at a separate location spatially remote from the electrodes.

25. The kit according to any one of claims 23 to 24, wherein The magnet is a permanent magnet or an electromagnet.